# Cigna Medical Coverage Policy- Therapy Services Low-Level Laser and High-Power Laser Therapy

Effective Date: 3/15/2023 Next Review Date: 3/15/2024





#### **INSTRUCTIONS FOR USE**

Cigna / ASH Medical Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document may differ significantly from the standard benefit plans upon which these Cigna / ASH Medical Coverage Policies are based. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Cigna / ASH Medical Coverage Policy. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Determinations in each specific instance may require consideration of:

- 1) the terms of the applicable benefit plan document in effect on the date of service
- 2) any applicable laws/regulations
- 3) any relevant collateral source materials including Cigna-ASH Medical Coverage Policies and
- 4) the specific facts of the particular situation

Cigna / ASH Medical Coverage Policies relate exclusively to the administration of health benefit plans.

Cigna / ASH Medical Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines.

Some information in these Coverage Policies may not apply to all benefit plans administered by Cigna. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make benefit determinations. References to standard benefit plan language and benefit determinations do not apply to those clients.

#### **GUIDELINES**

Low-level laser therapy is considered medically necessary for prevention of oral mucositis in patients undergoing cancer treatment associated with increased risk of oral mucositis, including chemotherapy and/or radiotherapy, and/or hematopoietic cell transplantation.

Low-level laser therapy (LLLT) is considered experimental, investigational or unproven for any other indication, including but not limited to:

- Wound healing
- Musculoskeletal pain; (e.g. back and neck pain, carpal tunnel syndrome, lateral epicondylitis, shoulder impingement, myofascial pain syndrome, fibromyalgia and others)
- Osteoarthritis and rheumatoid arthritis
- · Temporomandibular joint disorders

High-power Class IV therapeutic laser light therapy or similar therapeutic laser light therapy is considered experimental, investigational, or unproven for all indications.

#### **DESCRIPTION**

This Coverage Policy addresses low-level laser therapy (LLLT), also referred to as cold laser therapy, low-power laser therapy (LPLT), low-intensity laser and low-energy laser therapy and high power Class IV therapeutic laser light therapy.

This coverage policy does not address surgical lasers, which involve vaporizing tissue with hot lasers.

#### **GENERAL BACKGROUND**

Laser or low level laser therapy (LLLT) has been proposed as a modality used to accelerate and optimize the tissue repair process (Rocha et al., 2007). Laser stands for Light Amplification by Stimulated Emission of Radiation. LLLT is theoretically applied to photoactivate cellular mechanisms, leading to healing and normalization of tissue. The proposed result is reduced pain, inflammation, swelling, and accelerated tissue repair. Therapeutic lasers emit low-energy density but high enough to stimulate target cells with energy. Laser radiation is thought to be absorbed through cytochromes in the mitochondria and converted into ATP by the cell which acts to synthesize protein, mRNA and DNA, and accelerate cell proliferation based on the tissue receiving the light energy (Reddy 2004; Enwemeka 2004; Cameron, 2016).

More recently high power Class IV Therapeutic Laser Light Therapy devices have been used therapeutically. U.S. Food and Drug Administration (FDA) approved High Power Class IV therapeutic laser light therapy produces 7,500 miliwatts of continuous power. It is administered with a hand-held device and is thought to provide deeper penetration over a larger surface area. Per the manufacturer, Diowave (formerly Avicenna Laser Technology, Inc): the High Power, Class IV, therapeutic laser technology is used as a stand-alone modality to produce increased circulation, decreased inflammation, relaxation of muscle spasms and trigger points, accelerated tissue repair, and decreased pain at tissue sites previously unreachable by low-level stimulation. They are purported to stimulate accelerated healing energy from superficial to deep levels and a larger surface treatment area. Its proposed use includes conditions such as arthritis, carpal tunnel syndrome, epicondylitis, sprains/strains, trigger points and various other musculoskeletal disorders.

LLLT may be administered by several different types of providers, including physicians, chiropractors, physical therapists, or occupational therapists. It is generally provided in an office or other outpatient setting with no anesthesia or sedation needed.

#### **Evidence and Research**

There are numerous randomized trials on various applications of LLLT and some show positive results. The difficulty in interpreting these results is that they represent a wide range of conditions, methods of application, and characteristics of the laser instruments themselves. As such, it is difficult to come to any general conclusions regarding the effectiveness of LLLT. In 2006, the World Association of Laser Therapy (WALT) established effective parameters and methods of application as a guideline for investigators to follow. These guidelines state that power densities below 100 mW/cm2 should be used for superficial tendons with an energy dose range of 1-8 Joules. For deeper tendons of the rotator cuff, power densities can go as high as 600 mW/cm2, with an energy dose of 3-9 Joules. Wavelengths should be in the range of 780-904 nm. These guidelines allow researchers to selectively analyze studies that fall into these parameters to evaluate effectiveness (WALT, 2006).

#### <u>Literature Review – Joint Pain and Osteoarthritis (OA)</u>

Several systematic reviews have been published regarding LLLT for treatment of joint pain and osteoarthritis. In general they are inconsistent in the findings and do not substantiate the effective ness of this treatment for these conditions.

Bjordal et al. (2003) performed a systematic review that included 7 randomized, placebo controlled trials where an adequate dose of laser therapy was applied to a chronic joint disorder. These authors found a weighted mean difference of 29.84 mm on the pain visual analog scale (VAS) following laser treatment for knee pain, temporomandibular pain, or zygapophyseal joints. They concluded that LLLT significantly reduces pain and improves health status in chronic joint disorders when parameters are within the suggested dose range. However, the review also notes that the results should be cautiously interpreted due to the heterogeneity in patient samples, treatment procedures, and trial design.

A systematic review of rehabilitative interventions was conducted to assess various rehabilitative interventions on pain, function and physical impairments in hand osteoarthritis (Ye, et al., 2011). There were two studies included in the review that addressed LLLT. It was found that there was no effect on pain with LLLT, but it may be useful for improving range of motion.

A systematic review of conservative interventions for osteoarthritis of the hand concluded that there is moderate evidence that low-level laser therapy is no better than placebo in improving hand function or decreasing hand pain or stiffness (Valdes and Marik, 2010). An overview of systematic reviews for physical therapy interventions for knee osteoarthritis (OA) did confirm moderate evidence to support the effectiveness of low level laser therapy for knee OA (Ottawa Panel Evidence-Based Clinical Practice Guidelines, 2004; Jamtvedt et al., 2008). In a systematic review, Jang and Lee (2012) investigated the clinical effectiveness of LLLT on joint pain. Twenty-two trials were included consisting of 1014 patients. Eleven trials were positive and 11 were negative. The change in pain ratings was in favor of the active LLLT groups. In trials where the WALT guidelines were followed, the mean effect sizes were in favor of the true LLLT groups. This review supported the use of laser therapy for reduction of joint pain, especially when restricting the energy doses to the ranges stated in WALT guidelines.

Huang et al. (2015b) investigated the efficacy of low-level laser therapy (LLLT) treatment of knee osteoarthritis (KOA) by a systematic literature search with meta-analyses on selected studies. Nine Studies included were randomized controlled trials (RCTs) written in English that compared LLLT (at least eight treatment sessions) with sham laser in KOA patients dated from January 2000 to November 2014. No significant difference was identified in studies conforming to the World Association of Laser Therapy (WALT) recommendations (four studies) or on the basis of OA severity. There was no significant difference in the delayed response (12 weeks after end of therapy) between LLLT and control in VAS pain (five studies). Similarly, there was no evidence of LLLT effectiveness based on Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain, stiffness or function outcomes (five and three studies had outcome data right after and 12 weeks after therapy respectively). Authors concluded that their findings indicated the effectiveness of LLLT for patients with KOA is not supported based on the best available current evidence.

Dima et al. (2017) presented a summary of the possible pain management benefits of LLLT. LLLT, using the properties of coherent light, has been seen to produce pain relief and fibroblastic regeneration in clinical trials and laboratory experiments. LLLT has also been seen to significantly reduce pain in the acute setting; it is proposed that LLLT is able to reduce pain by lowering the level of biochemical markers and oxidative stress, and the formation of edema and hemorrhage. Many studies have demonstrated analgesic and anti-inflammatory effects provided by photobiomodulation in both experimental and clinical trials. Authors concluded that based on current research, the utilization of LLLT for pain management and osteoarthritic conditions may be a complementary strategy used in clinical practice to provide symptom management for patients suffering from osteoarthritis and chronic pain.

Alfredo et al. (2018) assessed the long-term effects of LLLT), in combination with strengthening exercises in patients with osteoarthritis of the knee. Forty participants of both genders, aged 50-75 years with knee osteoarthritis participated in the study. The LLLT group received 10 LLLT treatments with invisible infrared laser (904 nm, 3 Joules/point) over three weeks followed by an eight-week supervised strengthening exercise program. The placebo LLLT group received identical treatment, but the infrared laser output was disabled. The new data obtained during the follow-up period showed that all outcomes remained stable and there were no significant differences between the groups at three and six months. However, daily consumption of rescue analgesics was significantly lower in the LLLT group throughout the follow-up period, ending at a group difference of 0.45 vs. 3.40 units (P < 0.001) at six months follow-up. Authors concluded that within the limitations of this small study, the previously reported immediate post-intervention improvement after LLLT plus exercise was maintained for a period of six months.

Song et al. (2020) performed a systematic review and meta-analysis of randomized controlled trials to assess the effectiveness of HILT in patients with knee osteoarthritis. Six randomized controlled trials (RCTs) were included in this meta-analysis. For VAS pain, 334 patients from four studies showed that HILT significantly decreased pain compared to the control. HILT significantly improved WOMAC stiffness and function compared to the control. Authors concluded that the effectiveness of HILT on pain, stiffness, and function in patients with knee osteoarthritis is promising. However, due to the limited number of studies, further randomized controlled trials with large, well-designed samples are needed.

Cantero-Téllez et al. (2020) examined the effects of high-intensity laser therapy (HILT) on pain sensitivity and motor performance in patients with thumb carpometacarpal (CMC) osteoarthritis (OA). Forty-three patients (mean  $\pm$  SD age = 71  $\pm$  12 years) with a diagnosis of thumb CMC OA grade 1-2 were randomized to the control group (N = 21) or experimental group (N = 22). The experimental group (ExpG) received high-intensity laser therapy (HILT), and the control group (ConG) received a placebo treatment. The outcome measures were pain intensity (visual analog scale) and key pinch strength measurements (dynamometer). All outcome measures were collected at baseline, immediately following the intervention, at four weeks, and at 12 weeks following the intervention. Authors reported that HILT effectively diminishes pain intensity when used as an isolated treatment for patients with thumb CMC OA, but the effect of treatment decreases after 12 weeks.

Ahmad et al. (2022) examined the effects of LLLT or HILT combined with rehabilitation exercise (LLLT+E or HILT+E) on pain, stiffness and function in KOA. Of the 10 retrieved studies, six investigated LLLT+E, three on HILT+E, and one evaluated both. All the studies had high PEDro scores. However, as most of the studies employed a single type of laser therapy, only indirect comparison of LLLT+E and HILT+E was possible. This study found all treatment modalities were effective in reducing KOA symptoms. Interestingly, relative to control, the meta-analysis showed significant improvements in knee pain, stiffness and function for the HILT+E. Authors concluded that both LLLT and HILT are beneficial as adjuncts to rehabilitation exercise in the management of KOA. Based on an indirect comparison, the HILT+E seems to have higher efficacy in reducing knee pain and stiffness, and in increasing function. To confirm this finding, a direct comparative investigation of the two types of laser therapy may be necessary.

#### Literature Review - Shoulder Pain

Several systematic reviews have been published regarding LLLT for treatment of shoulder pain. In general they are inconsistent in the findings and do not substantiate the effective ness of this treatment for these conditions.

Haslerud et al. (2015) performed a systematic review with meta-analysis on shoulder tendinopathy and LLLT. The primary outcome measure was pain using the visual analogue scale (VAS) and relative risk for global improvement. Intervention quality assessments were performed of LLLT dosage and treatment procedures according to World Association for Laser Therapy guidelines. Seventeen randomized controlled trials (RCTs) met the inclusion criteria; 13 RCTs were of high and 4 RCTs of moderate methodological quality. Trials performed with inadequate laser doses were ineffective across all outcome measures. Otherwise this review demonstrated that optimal LLLT offers clinically relevant pain relief and improvement alone and in combination with other physical therapy interventions.

A systematic review for treatment of subacromial impingement did find laser therapy effective compared to placebo based on two RCTs, but it added no benefit when added to ROM exercises (Michener et al., 2004). Several randomized studies conducted for shoulder pain did not find significant results from the treatment with LLLT (Bal, et al., 2009; Dogan, et al., 2010; Abrisham, et al., 2011).

Aceituno-Gómez et al. (2019) evaluated the effectiveness of high-intensity laser therapy on shoulder pain and function in subacromial impingement syndrome. A total of 46 participants with subacromial impingement syndrome. A total of 21 patients in high-intensity laser therapy group and 22 patients in sham-laser group concluded the study. No differences were found between groups for pain and disability (P > 0.05). Authors concluded the effect of high-intensity laser therapy plus exercise is not higher than exercise alone to reduce pain and improve functionality in patients with subacromial syndrome.

Pieters et al. (2020) updated a systematic review published in 2013 that focused on evaluating the effectiveness of interventions within the scope of physical therapy, including exercise, manual therapy, electrotherapy, and combined or multimodal approaches to managing shoulder pain. Sixteen systematic reviews were retrieved. Results were summarized qualitatively. Relative to laser therapy, there was moderate evidence of no effect. Zhang et al. (2020) compared the efficacy of different nonsurgical interventions and identify potential patient-specific moderating factors for frozen shoulder. Of 3136 records identified, 92 trials were eligible, evaluating 32 nonsurgical interventions in 5946 patients. Laser therapy showed benefits for pain relief and functional improvement. Authors concluded that laser therapy show potential benefits for multiple outcomes.

Alfredo et al. (2021) investigated the effect of LLLT combined with exercise on shoulder pain and disability in patients with sub-acromial impingement syndrome (SIS). Patients (N=120) were enrolled and split into three

groups with one group receiving LLLT and exercise, another with just exercise, and the third group only receiving LLLT. Interventions were provided 3x per week for 8 weeks. Based on results, authors concluded that LLLT combined with exercise reduced pain and improved function over the 3 months to a greater degree than either alone.

## <u>Literature Review – Carpal Tunnel Syndrome</u>

Several systematic reviews have been published regarding LLLT for treatment of carpal tunnel syndrome. In general they are inconsistent in the findings and do not substantiate the effective ness of this treatment for these conditions.

The American Academy of Orthopaedic Surgeons (AAOS) published clinical practice guidelines on the treatment of carpal tunnel syndrome (AAOS, 2016). In the guidelines, regarding laser treatment, it is noted that, "Limited evidence supports that laser therapy might be effective compared to placebo." (Strength of Recommendation: Limited Evidence. Limited evidence: Evidence from one or more "Low" quality studies with consistent findings or evidence from a single "Moderate" quality study for recommending for against the intervention or diagnostic or the evidence is insufficient or conflicting and does not allow a recommendation for or against the intervention.)

Peters et al. (2013) reported on a Cochrane review that examined the effectiveness of rehabilitation following carpal tunnel syndrome (CTS) surgery compared with no treatment, placebo, or another intervention. The review found limited and low quality evidence for the benefit of the reviewed treatments, including laser therapy. The review included one quasi-randomized trial which compared LLLT to a placebo laser. This study found that there was no statistically significant difference in CTS symptoms with low-level laser therapy compared with a placebo. An update to this review (Peters, et al., 2016) included no new studies and similar findings regarding LLLT for rehabilitation following CTS.

Li et al. (2016) reported on a meta-analysis that was conducted to evaluate the effectiveness of low-level laser in the treatment of mild to moderate CTS using a Cochrane systematic review. The review included seven randomized clinical trials with 270 wrists in the laser group and 261 wrists in the control group with high heterogeneity noted when the analysis was conducted. Hand grip (at 12 weeks) was stronger in the LLLT group than in the control group and there was better improvement in the visual analog scale (VAS) (at 12 weeks) in the LLLT group. The sensory nerve action potential (SNAP) (at 12 weeks) was better in the LLLT group. It was noted that one included study was weighted at >95% in the calculation of these three parameters. There were no statistically significant differences in the other parameters between the two groups. The authors concluded that that low-level laser improved hand grip, VAS, and SNAP after three months of follow-up for mild to moderate CTS, however, additional high-quality studies using the same laser intervention protocol are needed to confirm the effects of low-level laser in the treatment of CTS.

Bekhet et al. (2017) performed a meta-analysis to investigate the efficacy of low-level laser therapy (LLLT) with anti-inflammatory and analgesic effects, in the management of mild-to-moderate carpal tunnel syndrome (CTS). Eight RCTs (473 patients/631 wrists) were eligible for the final analysis. The overall effect estimates did not favor LLLT therapy group over placebo in all primary outcomes: visual analogue scale, symptom severity scale score, and functional status scale score. However, LLLT was superior to placebo in terms of grip strength and inferior to placebo in terms of sensory nerve action potential. Authors concluded that laser therapy is superior to placebo in terms of improving the grip strength; however, no significant difference was found between both groups in terms of functional status improvement, pain reduction, or motor electrodiagnostic evaluations. Further high-quality trials with longer follow-up periods are required to establish the efficacy of LLLT for CTS treatment.

Franke et al. (2018) systematically reviewed the literature on the effectiveness of low-level laser therapy for patients with carpal tunnel syndrome. Strong evidence was found for the effectiveness of low-level laser therapy compared to placebo treatment in the very short term (0≤5 weeks). After five weeks, the positive effects of low-level laser therapy on pain, function, or recovery diminished over time (moderate and conflicting evidence were found at seven and 12-weeks follow-up, respectively). Authors concluded that in the very short term low-level laser therapy is more effective as a single intervention than placebo low-level laser therapy in patients with carpal tunnel syndrome, after which the positive effects of low-level laser therapy tend to subside. Evidence in the mid and long term is sparse.

Cheung et al. (2020) performed a network meta-analysis (NMA) for evaluating the effectiveness of LLLT compared with other conservative treatments for CTS. Six RCTs (418 patients) were included. NMA suggested that LLLT plus splinting has the highest probability (75%) of pain reduction, compared with sham laser plus splinting (61%), ultrasound plus splinting (57%) and splinting alone (8%). However, while LLLT plus splinting is significantly more effective than sham laser plus splinting for pain reduction, the magnitude is not clinically significant. Authors concluded that the effect of LLLT plus splinting on symptom severity and functional status was not superior to splinting alone. In an American Family Physician paper on nonpharmologic, noninvasive treatments for chronic musculoskeletal pain, Flynn (2020) reported that low reactive level laser therapy may provide short-term relief of chronic neck and low back pain, and ultrasound may provide short-term pain relief for knee osteoarthritis.

## Literature Review - Myofascial Pain

For myofascial pain, a randomized controlled study comparing laser treatment with placebo for treatment of myofascial pain found no differences in results between the groups, with both groups achieving some analgesic effect (Carrasco et al., 2009). In a randomized controlled trial of 63 participants with myofascial pain syndrome of the shoulder and neck area, Rayegani et al. (2011) compared LLLT, sham LLLT, and ultrasound (US) and measured pain using the VAS, disability using the Neck Disability Index (NDI), and an algometric assessment of improvement. Each group also received exercises. After 10 sessions of daily treatment, results demonstrated that use of laser therapy demonstrated significant improvements when compared with the sham laser group and also between pre- and post-intervention scores in pain and NDI. There were no significant differences related to pain between LLLT and US; however, the NDI showed more improvement with laser treatment. The authors recommended further study with larger patient populations (Rayegani et al., 2011).

Tehrani et al. (2022) evaluated the effectiveness of LLLT on mechanical neck pain (MNP). A total of 13 randomized controlled trials were included in this systematic review and meta-analysis. The data assessing laser effectiveness on different outcomes of 556 patients were considered for meta-analysis. Pooled results revealed that LLLT was significantly effective in pain reduction. Also, secondary outcomes including pain pressure threshold (PPT) and right bending ROM were improved, while disability did not improve significantly after LLLT. Authors concluded that this meta-data revealed that LLLT may reduce myofascial neck pain and its related outcomes. Alayat et al. (2022) aimed to investigate the efficacy of photobiomodulation therapy (PBMT) on pain and pressure pain threshold (PPT) in patients with myofascial pain syndrome (MPS) of the upper trapezius muscle in a systematic review. A total of 17 studies (944 patients) were included. A meta-analysis was performed on 16 studies. Assessment according to the PEDro scale revealed 12 high-quality, 3 fair-quality, and 2 low-quality studies. Authors conclude that the present systemic review revealed that PBMT is an effective PT modality for reducing pain and increasing PPT in patients with MPS of the upper trapezius. PBMT, when combined with EX, had more significant effects in reducing pain and increasing PPT compared with controls. The low-quality studies with low to moderate quality of evidence limit the confidence of findings and recommend further high-quality studies for standardization of treatment protocols and irradiation parameters.

#### Literature Review - Low Back Pain

Several systematic reviews have been published regarding LLLT for treatment of low back pain. In general they are inconsistent in the findings and do not substantiate the effective ness of this treatment for these conditions.

Yousefi-Nooraie et al. (2008) conducted a Cochrane review that included seven studies and examined LLLT for nonspecific low-back pain. The authors concluded that based on the heterogeneity of the populations, interventions and comparison groups, "that there are insufficient data to draw firm conclusion on the clinical effect of LLLT for low-back pain." In addition the authors note that there is a need for further methodologically rigorous randomized, controlled trials to evaluate the effects of LLLT compared to other treatments, different lengths of treatment, wavelengths and dosage.

A review of evidence was conducted for the development of an American Pain Society /American College of Physicians clinical practice guideline for diagnosis and treatment of low back pain (Chou and Huffman, 2007). The review examined nonpharmacologic therapies for acute and chronic low back pain and included only systematic reviews and randomized trials, with seven trials that included LLLT. Four trials found laser therapy superior to sham for pain or functional status up to one year after treatment, but another higher-quality trial found no differences between laser and sham in patients receiving exercise. One lower-quality study reported found similar results for laser, exercise and the combination of laser plus exercise for pain and back-specific

functional status. It was noted that optimal treatment parameters, wavelength, dosage, dose intensity are uncertain.

Glazov et al. (2016) reported on a systematic review to determine if LLLT (including laser over acupuncture points) has specific benefits in chronic non-specific low back pain (CNLBP). The review included 15 studies with 1039 participants. The results at immediate and short-term follow-up there was significant pain reduction of up to WMD (weighted mean difference) -1.40 cm in favor of laser treatment, occurring in trials using at least 3 Joules (J) per point, with baseline pain <30 months and in non-acupuncture LLLT trials. Global assessment showed a risk ratio of 2.16 (95% CI 1.61 to 2.90) in favor of laser treatment in the same groups only at immediate follow-up. While there appears to a benefit with LLLT in the short term, further randomized studies with blinding and longer follow-up are needed to determine the appropriate laser dosage.

Huang et al. (2015b) completed a systematic review and meta-analysis on the effectiveness of low-level laser therapy for nonspecific chronic low back pain. Among 221 studies, seven trials met inclusion criteria. Based on five studies, pain outcome scores were significantly lower for the LLLT group compared with placebo. No significant treatment effect was identified for disability scores or spinal range of motion. The authors concluded that findings indicate LLLT is an effective method for relieving pain in non-specific chronic low back pain (NSCLBP) patients, which contradicts other previous findings.

The Agency for Healthcare Research and Quality (AHRQ) published a review of the comparative effectiveness of non-invasive treatments for low back pain (Chou, et al., 2016). The review included randomized, controlled trials, along with systematic reviews of randomized controlled trials. Regarding LLLT for acute back pain, the strength of evidence (SOE) was found to be insufficient, and for LLLT for chronic back pain, the SOE was found to be low to insufficient. Among the findings of the review for LLLT for back pain:

- For acute low back pain, insufficient evidence from one trial to determine effectiveness of low-level laser therapy versus sham laser, due to serious methodological shortcomings and imprecision (Strength of evidence [SOE]: insufficient).
- For chronic low back pain, three of four trials found low-level laser therapy more effective than sham laser for pain, with the methods for assessing pain and duration of follow-up varied; two trials found low-level laser therapy more effective than sham laser for function, with small magnitude of effects (SOE: low for pain and function).
- For chronic low back pain, there was insufficient evidence from three trials to determine effects of low-level laser therapy plus exercise versus the other sham laser plus exercise alone, due to methodological shortcomings and inconsistency (SOE: insufficient).
- There was insufficient evidence to determine effects of low-level laser therapy versus another intervention, due to methodological shortcomings and imprecision (SOE: insufficient).
- There was insufficient evidence to determine effects of different wavelengths of low-level laser therapy or different doses, due to methodological limitations and imprecision (SOE: insufficient).

Choi et al. (2017) examined the effects of High Intensity Laser Therapy on pain and function of patients with chronic back pain. This study evenly divided a total of 20 patients with chronic back pain into a conservative physical therapy group that received conservative physical therapy, and a high intensity laser therapy group that received High Intensity Laser Therapy after conservative physical therapy. All patients received the therapy three times a week for four weeks. For the high intensity laser therapy group, treatment was applied to the L1-L5 and S1 regions for 10 minutes by using a high intensity laser device while vertically maintaining the separation distance from hand-piece to skin at approximately 1 cm. A visual analog scale was used to measure the pain and Oswestry Disability Index was used for functional evaluation. In a within-group comparison of the conservative physical therapy and high intensity laser therapy groups, both the visual analog scale and Oswestry Disability Index significantly decreased. In a between-group comparison after treatment, the high intensity laser therapy group showed a significantly lower visual analog scale and Oswestry Disability Index than the conservative physical therapy group. Authors concluded that High Intensity Laser Therapy can be an effective nonsurgical intervention method for reducing pain and helping the performance of daily routines of patients who have chronic back pain. In a report published by the Agency for Healthcare Research and Quality on Noninvasive Nonpharmacological Treatment for Chronic Pain, authors state that function improved over short and/or intermediate term for exercise, low-level laser therapy (Skelly et al., 2020) (SOE: low). This report included 233 RCTs (31 new to this update). Many were small (N<70), and evidence beyond 12 months after treatment completion was sparse. The most common comparison was with usual care. Evidence on harms was

limited, with no evidence suggesting increased risk for serious treatment-related harms for any intervention. Effect sizes were generally small for function and pain.

## **Literature Review - Neck Pain**

Several systematic reviews have been published regarding LLLT for treatment of neck pain. In general they are inconsistent in the findings and do not substantiate the effective ness of this treatment for these conditions. A meta-analysis and systematic review by Chow et al. (2009) concluded that there is moderate evidence that low level laser therapy reduces pain immediately after treatment in subjects with chronic neck pain and up to 22 weeks after treatment. Low level laser therapy compares favorably with pharmacologic interventions, with no adverse reactions or side effects (Chow et al., 2009). However, reviewers of the systematic review have expressed concerns regarding statistical application and the highly heterogeneous nature of the groups in terms of diagnosis and treatments (Verhagen and Schellingerhout, 2010; Shiri and Viikari-Juntara et al., 2010).

In 2013, Kadhim-Saleh et al. attempted to determine the efficacy of LLLT in reducing acute and chronic neck pain. Eight RCTs involving 443 patients were selected. Five trials included patients with cervical myofascial pain syndrome (CMPS), and three trials had a variety of patient conditions. Results of the review provided inconclusive evidence because of heterogeneity and potential risk of bias. Any benefit noted, although significant from a statistical standpoint, did not reach the threshold of a minimally important clinical difference.

Gross et al. (2013) evaluated LLLT for adults with neck pain. Their systematic review noted moderate quality evidence for chronic neck pain supporting LLLT over placebo to improve pain and disability, and quality of life into the intermediate term. Low quality evidence suggested LLLT improved short term pain and function over placebo for acute radiculopathy, cervical osteoarthritis or acute neck pain. For chronic myofascial neck pain (5 trials, 188 participants), evidence was conflicting. Authors conclude that LLLT may be beneficial for chronic neck pain, function and improvement of quality of life but long term trials are needed.

Wong et al. (2016) aimed to update the findings of the Neck Pain Task Force, which examined the effectiveness of manual therapies, passive physical modalities, and acupuncture for the management of whiplash-associated disorders (WAD) or neck pain and associated disorders (NAD). The review found new evidence suggesting that LLLT is not effective for persistent NAD grades I–II. However, when combining the new evidence with Neck Pain Task Force findings from five studies, the preponderance of evidence suggests that clinic-based LLLT is effective for persistent NAD.

In the American Physical Therapy Association Orthopedic Section Clinical Practice Guideline on Neck Pain revised I 2017, it is recommended that for patients with chronic neck pain with mobility deficits, clinicians should provide a multimodal approach of the following: thoracic manipulation and cervical manipulation or mobilization; mixed exercise for cervical/scapulothoracic regions: neuromuscular exercise (e.g., coordination, proprioception, and postural training), stretching, strengthening, endurance training, aerobic conditioning, and cognitive affective elements; dry needling, laser, or intermittent mechanical/manual traction (Grade B) (Blanpied et al., 2017).

In a report published by the Agency for Healthcare Research and Quality on Noninvasive Nonpharmacological Treatment for Chronic Pain, authors state that short-term low-level laser therapy was associated with moderate improvement in function and pain (Skelly et al., 2018). This report was updated in 2020 that included 233 RCTs (31 new to this update). Many were small (N<70), and evidence beyond 12 months after treatment completion was sparse. The most common comparison was with usual care. Evidence on harms was limited, with no evidence suggesting increased risk for serious treatment-related harms for any intervention. Effect sizes were generally small for function and pain. For chronic neck pain, in the short term, low-level laser therapy (SOE: moderate)

#### **Literature Review – Achilles Tendinopathy**

One study of 52 recreational athletes with Achilles tendinopathy compared eccentric exercise plus either laser or placebo treatments administered twice per week for 4 weeks, followed by once per week for 4 weeks. The laser group had significantly greater improvements in pain VAS, stiffness, ROM, and tenderness at 4, 8, and 12 weeks (Stergioulas et al., 2008). Turnilty et al. (2008) used low level laser therapy applied to points on the tendon 3 times a week for 12 weeks and noted significant improvement in all outcome measures at 4 and 12 weeks. However, the authors determined that conclusions regarding effectiveness could not be made due to the low statistical power of the study.

The Orthopaedic Section of the American Physical Therapy Association (APTA) published clinical practice guidelines for Achilles pain, stiffness, and muscle power deficits (Carcia, et al., 2010). The guidelines note that based on limited works, the future of LLLT is promising for patients suffering from Achilles tendon pain. Given the limited number of studies employing LLLT in this population, additional study is warranted. Clinicians should consider the use of low-level laser therapy to decrease pain and stiffness in patients with Achilles tendinopathy. (Level B).

\*Level B: Moderate evidence - A single high-quality randomized controlled trial or a preponderance of level II studies support the recommendation

Martimbianco et al. (2020) determined the benefits and harms of low-level laser therapy for Achilles tendinopathy. Four trials (119 participants) were analyzed. Laser therapy associated to eccentric exercises when compared to eccentric exercises and sham had very low to low certainty of evidence in pain and function assessment. The function assessment showed an improvement favoring the placebo group at one month and non-significant difference between groups at 3 and 13 months. Adverse events were poorly reported but restricted to minor events related to the exercises. Authors concluded that the certainty of evidence was low to very low, and the results are insufficient to support the routine use laser therapy for Achilles tendinopathy.

## <u>Literature Review – Plantar Fasciitis</u>

Guimarães et al. (2022) investigated the effects of low-level laser therapy (LLLT) on pain and disability in patients with plantar fasciitis (PF). Three comparisons were made: LLLT compared with placebo, LLLT combined with conventional rehabilitation (CR) compared with CR and LLLT compared with extracorporeal shock wave therapy. Fourteen studies (817 patients) met the study criteria. Compared to the placebo group, LLLT improved pain (moderate-quality evidence) in the short term (0-6 weeks). No significant difference in shortterm disability was found for participants in the LLLT group compared to the placebo group. Compared to the CR group, LLLT combined with CR improved pain (moderate-quality evidence) in the short term (0-6 weeks). Compared to extracorporeal shock wave therapy, LLLT did not significantly reduce pain intensity in the short term (low-quality evidence). Authors concluded that LLLT may improve pain in the short term and can be considered as a component of care of patients with PF. However, this superiority disappeared compared to extracorporeal shock wave therapy. Naterstad et al. (2022) investigated the effectiveness of low-level laser therapy (LLLT) in lower extremity tendinopathy and plantar fasciitis on patient-reported pain and disability. Only randomized controlled trials involving participants with lower extremity tendinopathy or plantar fasciitis treated with LLLT were included. LLLT was compared with placebo (10 trials), other interventions (5 trials) and as an add-on intervention (3 trials). The study quality was moderate to high. Overall, pain was significantly reduced by LLLT at completed therapy and 4-12 weeks later. Overall, disability was significantly reduced by LLLT at completed therapy and 4-9 weeks later. Compared with placebo control, the recommended doses significantly reduced pain at completed therapy and 4-8 weeks later. The recommended doses significantly reduced pain as an add-on to exercise therapy versus exercise therapy alone at completed therapy and 4-9 weeks later. No adverse events were reported. Authors concluded that LLLT significantly reduces pain and disability in lower extremity tendinopathy and plantar fasciitis in the short and medium term. Long-term data were not available.

#### Literature Review - Lateral Epicondylitis

Several systematic reviews have been published regarding LLLT for treatment of lateral epicondylitis. In general they are inconsistent in the findings and do not substantiate the effective ness of this treatment for these conditions.

Dingemanse et al. (2013) performed a systematic review of the effectiveness of electrophysical modalities for the treatment of medial and lateral epicondylitis. A total of 2 reviews and 22 RCTs were included and evaluated, all of which concerned lateral epicondylitis. Ultrasound plus friction massage showed moderate effectiveness over LLLT on short term follow up. Moderate evidence was found in favor of LLLT over plyometric exercises on short term follow up (Dingemanse et al., 2013).

Sims et al. (2014) completed a systematic review of treatments for lateral epicondylitis. They noted that LLLT demonstrates superiority over placebo in some studies and not in others. They determined that the evidence is insufficient to draw conclusions that there is one preferred method of non-surgical treatment for this condition. Dion et al. (2017) evaluated the effectiveness of passive physical modalities for the management of soft tissue injuries of the elbow. Twenty-one were eligible for critical appraisal and (reporting on eight randomized controlled trials) had a low risk of bias. Authors found that adding transcutaneous electrical nerve stimulation to primary care does not improve the outcome of patients with lateral epicondylitis. They found inconclusive

evidence for the effectiveness of: (1) an elbow brace for managing lateral epicondylitis of variable duration; and (2) shockwave therapy or low-level laser therapy for persistent lateral epicondylitis. Authors conclude that their review found little evidence to inform the use of passive physical modalities for the management of elbow soft tissue injuries.

A systematic review concluded that low-level laser therapy administered directly to the lateral elbow tendon insertions may offer short-term pain relief and decreased disability, both alone and in conjunction with an exercise program (Bjordal et al., 2008). A systematic review of literature on treatments for lateral epicondylitis did not support the use of low level laser therapy (Trudel et al., 2004).

Lian et al. (2018) compared the efficacy and safety of nonsurgical treatment options for eECRB described in randomized placebo-controlled trials at short-term, midterm, and long-term follow-up and (2) evaluate outcomes in patients receiving placebo. Thirty-six randomized placebo-controlled trials, evaluating 11 different treatment modalities, with a total of 2746 patients were included. At midterm follow-up, laser therapy and local botulinum toxin injection improved pain.

#### Literature Review - Rheumatoid Arthritis

A Cochrane systematic review (Brosseau, et al., 2005) was performed for the purpose of reviewing literature regarding the use of LLLT as treatment for rheumatoid arthritis (RA). Six studies with 220 patients with rheumatoid arthritis were included in the review. The main limitation with the studies is the heterogeneity of clinical application. In addition, the results are subject to publication bias, if negative trials have not been published. It was concluded in this review that "this meta-analysis found that pooled data gave some evidence of a clinical effect, but the outcomes were in conflict, and it must therefore be concluded that firm documentation of the application of LLLT in RA is not possible. Conversely, a possible clinical benefit in certain subgroups cannot be ruled out from the present meta-analysis and further large scaled studies are recommended with special attention to the findings in this meta-analysis (e.g., low versus high dose wavelength, nerve versus joint application, and treatment duration)."

The Ottawa Panel Evidence-Based Clinical Practice Guidelines reviewed the same set of RCTs using the Cochrane method and concluded there was strong evidence in support of a clinically important benefit for low level laser treatment of foot, knee, or hand pain for patients with rheumatoid arthritis (RA) (Ottawa Panel Evidence-Based Clinical Practice Guidelines, 2004). Their findings were based on positive findings in 4 out of 5 placebo-controlled RCTs, with pain reduction ranging from 19 – 28%. A later review of systematic reviews concluded that there is evidence that low-level laser therapy generally reduces pain and improves function (Christie et al., 2007). A randomized controlled study of LLLT concluded that it was not specifically effective for the treatment of hand pain in patients with rheumatoid arthritis (Meireles, et al., 2010).

## <u>Literature Review - Temporomandibular Joint Dysfunction (TMJ or TMD)</u>

Several systematic reviews have been published regarding LLLT for treatment of temporomandibular joint dysfunction (TMJ or TMD). In general they are inconsistent in the findings and do not substantiate the effective ness of this treatment for these conditions.

Chang et al. (2014) completed a systematic review of selected studies of randomized controlled trials and calculated the effect size (ES) of the pain relief to evaluate the effect of LLLT. Seven studies met inclusion criteria. Results indicated a moderate effect of pain relief. Also, the dosages and treatments with wavelengths of 780 and 830 nm created moderate and large pain relief effects. Authors concluded that use of LLLT for TMJ pain had a moderate analgesic effect. They agree that the optimal parameters for LLLT to treat TMJ pain have not been confirmed.

A systematic review and meta-analysis assessed the evidence for LLLT for Temporomandibular Disorders (TMD) (Petrucci, et al., 2011). Six randomized clinical trials were included in the review. The primary outcome was the change in pain from baseline to endpoint. The pooled effect of LLLT on pain, measured through a visual analog scale was not statistically significant from placebo. The authors concluded that there is no evidence to support the effectiveness of LLLT in the treatment of TMD.

Maia et al. (2012) reported on a systematic review of LLLT on pain levels in patients with temporomandibular disorders (TMD). The review included 14 studies, with 12 studies utilizing a placebo group. The number of sessions varied along with the frequency of applications. There was a range in the energy density and power

density used. It was found that there was a reduction in pain levels reported in 13 studies, with nine of these occurring only in the experimental group and four studies reporting pain relief for both experimental and placebo group. The authors concluded that while LLLT appeared to be effective in reducing pain, due to the heterogeneity in standardization of parameters of laser there should be caution in interpretation of the results. Further research is needed regarding appropriate application laser protocol.

Xu et al. (2018) systematically reviewed randomized controlled trials (RCTs) of the effect of low-level laser therapy (LLLT) versus placebo in patients with temporomandibular disorder (TMD). A total of 31 RCTs were included. Combining data from all clinically heterogeneous studies revealed positive effects of LLLT on pain relief, regardless of the visual analogue scale (VAS) score or the change of VAS score between the baseline and the final follow-up time point, while dosage analyses showed discrepant results about the effects of high or low doses for patients with TMD. Follow-up analyses showed that LLLT significantly reduced pain at the short-term follow-up. Temporomandibular joint function outcomes indicated that the overall effect favored LLLT over placebo. Authors suggest that from this review, LLLT effectively relieves pain and improves functional outcomes in patients with TMD.

In a systematic review, de Pedro and colleagues (2020) examined the efficacy of LLLT for the management of neuropathic orofacial pain. The primary outcome was measurement of pain intensity. A total of 997 studies were obtained with the initial search; 13 (8 RCTs, 2 prospective studies, and 3 case series) met the inclusion criteria and were analyzed for data extraction; 3 provided data for the treatment of trigeminal neuralgia (TN), 1 for occipital neuralgia, and 10 for BMS. All studies showed a reduction in pain intensity (most of them significant). The different studies analyzed LLLT alone and compared to placebo, to another treatment, or to different LLLT application protocols. The authors concluded that LLLT appeared to be effective as a therapeutic option for different neuropathic orofacial pain entities such as TN, occipital neuralgia, and BMS as a single or combined treatment. Moreover, these researchers stated that more quality studies assessing all outcome measures of chronic pain are needed in the medium- and long-terms. Furthermore, due to the lack of standardization of the application technique, more well-designed studies are needed to confirm the results of this systematic review.

Ahmad et al. (2021) evaluated the efficacy of LLLT in the treatment of temporomandibular joint disorder within a systematic review. Thirty-seven articles were considered eligible for this systematic review. Out of 37 studies, 33 (89.18%) are high methodological studies, which have an overall low risk of bias or with some concerns, while only 4 studies have a high risk of bias. Eighteen studies showed that LLLT was efficacious in diminishing TMD pain, whereas 12 studies showed that LLLT had similar efficacy as of placebo/controls/other intervention in TMD pain diminution. Four studies presented varied effects of LLLT on pain intensity, mandibular motion, EMG activity, and masticatory efficiency. Two studies revealed that LLLT improved the psychological and emotional aspects associated with TMDs, joint noises, masticatory efficiency, and EMG parameters, respectively. One study focused on subjective tinnitus, whereas another study suggested laser acupuncture (LAT) therapy as a suitable alternative to LLLT. The results demonstrate that LLLT appears to be efficient in diminishing TMD pain with variable effects on the outcome of secondary parameters. The results demonstrate that LLLT appears to be efficient in diminishing TMD pain with variable effects on the outcome of secondary parameters. Also, LLLT provides advantages as the therapeutic regimen is non-invasive, reversible, with fewer adverse effects, and may also improve the psychological and emotional aspects associated with TMDs. Therefore, this systematic review highlights the role of LLLT as a promising therapeutic regimen for TMDs.

Ren et al. (2022) assessed the efficacy of low-level laser therapy (LLLT) with different wavelengths and transcutaneous electric nerve stimulation (TENS) and explore the optimal wavelength range of laser application in the treatment of pain caused by temporomandibular disorders (TMD). Twenty-seven RCTs with 969 patients with TMD were included. In the meta-analysis, all treatment groups showed an overall improvement in pain scores, when compared with the placebo group. LLLT with wavelength ranging from 910 nm to 1100 nm produced more pain relief in the visual analogue scale (VAS) immediately after treatment. After one-month follow-up, LLLT with wavelength ranging from 910 nm to 1100 nm also showed superior pain-relieving effects. However, no significant difference was observed. Authors concluded that the results of the meta-analysis showed the LLLT had better short-term efficacy than TENS in the treatment of pain caused by TMD. Better results can be achieved with higher wavelengths. Therefore, authors recommended to treat TMD using LLLT with wavelength ranging from 910 nm to 1100 nm.

#### Literature Review—Wound Healing

There are several systematic technical reviews published regarding the use of low level laser for wound healing. The Agency for Healthcare Research and Quality (AHRQ) published a review of the comparative effectiveness and harms of different therapies and approaches to treating pressure ulcers (Saha, et al., 2013). Regarding low-level laser therapy, the review found low strength of evidence for laser therapy and that wound improvement was similar with laser therapy compared with sham treatment or standard care (four studies). Beckmann et al. (2014) completed a systematic literature review of LLLT for wound healing of diabetic ulcers. They concluded that although the majority of clinical studies show a potential benefit of LLLT in wound healing of diabetic ulcers, there are several aspects in these studies limiting final evidence about the actual outcomes. In summary, all studies give enough evidence to continue research on laser therapy for diabetic ulcers, but clinical trials using human models do not provide sufficient evidence to establish the usefulness of LLLT as an effective tool in wound care regimes at present. Further well designed research trials are required to determine the true value of LLLT in routine wound care.

Huang et al. (2021) performed a meta-analysis to evaluate the effect of LLLT on diabetic foot ulcers (DFUs). A total of 13 randomized controlled trials (RCTs) and 413 patients were analyzed. Compared with the control group, LLLT significantly increased the complete healing rate, reduced the ulcer, and shortened the mean healing time of patients with DFUs. The quality of the evidence was very low according to the GRADE system. Authors concluded that LLLT is a promising and effective adjuvant treatment to accelerate the healing of DFUs. Further evidence from larger samples and higher quality RCTs is needed to prove the effect of LLLT and to determine the most appropriate parameters for the healing of DFUs.

#### Literature Review—Oral Mucositis

A systematic review and meta-analysis was conducted to examine the effect of LLLT in cancer therapy-induced oral mucositis (OM). The review included 11 randomized, placebo-controlled trials with 415 patients (Bjordal, et al., 2011). The study found consistent evidence from small high-quality studies that red and infrared LLLT can partially prevent development of cancer therapy-induced OM. LLLT also significantly reduced pain, severity and duration of symptoms in patients with cancer therapy-induced OM. The limitation of the study included the small sample size of the included trials and the heterogeneity of the treatment procedures and dosing. Clarkson et al. (2010) reported on a Cochrane review to assess the effectiveness of interventions for treating oral mucositis or its associated pain in patients with cancer receiving chemotherapy or radiotherapy or both. The review found that there is limited evidence from two small trials that low level laser treatment reduces the severity of the mucositis. The authors concluded that there is weak and unreliable evidence that low level laser treatment reduces the severity of the mucositis with a need for further, well designed, placebo or no treatment controlled trials assessing the effectiveness of interventions for mucositis.

Lalla et al. (2014) updated a previous version of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis in a systematic review. The literature search identified 8279 papers, 1032 of which were retrieved for detailed evaluation based on titles and abstracts. Of these, 570 qualified for final inclusion in the systematic reviews. Sixteen new guidelines were developed for or against the use of various interventions in specific treatment settings. In total, the MASCC/ISOO Mucositis Guidelines now include 32 guidelines: 22 for oral mucositis and 10 for gastrointestinal mucositis. Authors reviewed 24 studies evaluating the effects of laser or other light therapy on oral mucositis. The evidence supported the development of 2 new guidelines: a recommendation in favor of low-level laser therapy (LLLT) for the prevention of oral mucositis in patients receiving high-dose chemotherapy (CT) for hematopoietic stem cell transplantation (HSCT) with or without total body irradiation, and a suggestion for LLLT in the prevention of oral mucositis in patients receiving head and neck radiation therapy (H&N RT) without concomitant chemotherapy.

This clinical practice guideline was updated again in 2021 (Elad et al.). This current guideline update has several new insights:

- A recommendation for the prevention of OM with intraoral photobiomodulation (PBM) therapy (previously laser or light therapy) in patients who undergo HSCT
  - Current systematic review reiterates the 2014 guidelines in this patient population and increases the range of PBM settings that may be used;
- A recommendation for the prevention of OM with intraoral PBM therapy in patients with cancer who
  receive H&N RT (without CT)
  - This is an upgrade of the 2014 guidelines from a suggestion to a recommendation

- A recommendation for the prevention of OM with intraoral PBM therapy in patients with cancer who
  receive H&N RT with CT
  - This new guideline is based on recent evidence.

The authors also identified several RCTs aimed at the treatment of OM in pediatric patients undergoing mixed RT/RT-CT, mixed HSCT/CT, or CT for several types of cancer. The results were promising; however, it was too early to base a guideline on these findings. Authors also reported that recent long-term follow-up studies on patients treated with PBM for the prevention of OM showed no increase in cancer recurrence. However, the analysis of these data is challenging. Considering the conflicting evidence from animal models regarding the effect of PBM on tumor behavior, the clinician is advised to inform patients about the expected benefits and potential risks of PBM. They also state that PBM protocols described in this guideline should be followed exactly to optimize clinical efficacy.

He et al. (2018) aimed to synthesize the available clinical evidences on the effects of low-level laser therapy (LLLT) in the prevention and treatment of chemotherapy-induced oral mucositis (OM). Authors found 8 qualified clinical trials with a total of 373 pediatric patients; Authors concluded that prophylactic LLLT reduces mucositis and severe mucositis and decreases the average severity of oral mucositis in pediatric and young patients with cancer. Therapeutic LLLT also reduces the average severity of oral mucositis and oral pain.

de Lima et al. (2020) sought to determine the effectiveness of low-level laser therapy in preventing oral mucositis in patients undergoing chemoradiotherapy for head and neck cancer in a systematic review and meta-analysis. From 14,525 records, only 4 studies were included in the review and 3 studies were included in meta-analysis. Data from 500 patients (mean age of 53.595 and 54.14 for intervention and control groups, respectively) were analyzed. Meta-analysis showed that laser therapy prevents oral mucositis incidence in 28% and 23% of cases during the third and fourth follow-up week, respectively, in comparison to a placebo-treated control group. There was no statistically significant difference the prevention of pain. Dysphagia and quality of life were not analyzed due to missing data. The authors concluded that laser therapy was effective in preventing oral mucositis from the 15th to the 45th days of chemoradiotherapy. However, new primary studies with low risk of bias are needed so a higher scientific evidence can be obtained.

Patel et al. (2021) updated the 2015 clinical practice guideline for the prevention of oral mucositis in pediatric cancer or hematopoietic stem cell transplant (HSCT) patients. They performed seven systematic reviews of mucositis prevention. Three reviews included randomized controlled trials (RCTs) conducted in pediatric and adult patients evaluating cryotherapy, keratinocyte growth factor (KGF) or photobiomodulation therapy with a focus on efficacy. Authors included 107 unique studies of cryotherapy (22 RCTs and 4 pediatric studies); KGF (15 RCTs and 12 pediatric studies); photobiomodulation therapy (29 RCTs and 8 pediatric studies) and any intervention (31 pediatric RCTs). Effect on severe mucositis reduction from RCTs was photobiomodulation therapy Risk Ratio 0.40 and 95% CI 0.27-0.60. Cryotherapy was not feasible in young children while photobiomodulation therapy was feasible across age groups. Relative to Intraoral photobiomodulation therapy (620-750 nm spectrum) only, this intervention should be used in pediatric patients undergoing autologous or allogeneic HSCT and for pediatric head and neck carcinoma patients undergoing radiotherapy.

Redman et al. (2022) assesses the efficacy of oral low-level laser therapy (LLLT) - also known as photobiomodulation - in the reduction of oral mucositis experienced by children and young people with cancer undergoing chemotherapy. Primary outcomes included severity of oral mucositis, oral pain and adverse events. 14 studies (n>416 children) were included in the narrative synthesis of LLLT efficacy. 5 studies (n=380 children and young people) were included in the meta-analyses. Results demonstrate that LLLT may reduce the severity of oral mucositis and the level of oral pain, but further randomized controlled trials are needed to confirm or deny this. There is vast variation in different trial protocols. Insufficient blinding between LLLT or sham therapy/control led to a strong risk of performance bias. 75 studies (encompassing 2712 patients of all ages who had undergone LLLT) demonstrated minor and infrequent adverse reactions, but most studies had significant areas of weakness in quality. Authors concluded that LLLT appears to be a safe therapy, but further evidence is needed to assess its efficacy as a prevention or treatment tool for oral mucositis in children with cancer.

Biala (2022) reviewed evidence on the effectiveness of LLLT using diode lasers on the prevention and reduction in severity of OM in patients with cancer undergoing HSCT. Six randomized controlled trials and one cohort study met the inclusion criteria. The author concluded that the data demonstrate promising outcomes for

reducing the incidence and severity of OM using LLLT. Larger, tightly controlled clinical trials are needed in the future.

#### **Literature Review - Musculoskeletal Conditions**

Several studies have been published regarding LLLT for musculoskeletal conditions. Limitations of the studies included small study size, short follow-up time periods, and heterogeneity in terms of laser, dose, duration and frequency of treatments (Dakowicz, et al., 2011; Tascioglu, et al., 2012; Konstantinovic, et al., 2010; Ay, et al., 2010; Oken, et al., 2008; and Djavid, et al., 2007).

Clijsen et al. (2017) completed a systematic review and meta-analysis on the effects of low level laser therapy on pain in patients with musculoskeletal disorders. A random-effects model was used for this meta-analysis. Subgroup meta-analyses were conducted to evaluate the influence of the adherence of the applied LLLT to the World Association of Laser Therapy (WALT) guidelines, the anatomical site under investigation and the study design on the overall weighted mean effect size. Meta regression was used to assess the possible influence of the study quality on the individual study effect sizes. Eighteen studies allowing for 21 head-to-head comparisons (totaling n=1462 participants) were included. The pooled raw mean difference (D) in pain between LLLT and the control groups was -0.85. There was high and significant between study heterogeneity. The subgroup meta-analysis of the comparisons not following the WALT guidelines revealed a D = -0.68. In this group, heterogeneity decreased. In the WALT subgroup D equaled -1.52. This between groups difference was clinically relevant although statistically not significant. Authors conclude that this meta-analysis presents evidence that LLLT is an effective treatment modality to reduce pain in adult patients with musculoskeletal disorders. Adherence to WALT dosage recommendations seems to enhance treatment effectiveness.

The Royal Dutch Society for Physical Therapy (KNGF) issued a clinical practice guideline for physical therapists that addresses the assessment and treatment of patients with nonspecific neck pain, including cervical radiculopathy, in Dutch primary care. Recommendations were based on a review of published systematic reviews. The physical therapist is advised not to use dry needling, low-level laser, electrotherapy, ultrasound, traction, and/or a cervical collar (Bier et al., 2018).

Song et al. (2018) investigated the effectiveness of high intensity laser therapy (HILT) for musculoskeletal disorders using a systematic review and meta-analysis. Twelve studies were selected for this systematic review. In 11 studies, comprising 736 patients, pain was significantly improved by HILT compared with a control group. From the analysis of 688 patients from 10 studies, HILT showed a significant improvement in disability scores compared with those in the control group. The results of this study show that HILT treatment for back and neck pain significantly improved pain and disability scores compared with controls.

The National Institute for Health and Care Excellence (NICE) (2021) completed an evidence review to explore the effectiveness of electrical physical modality interventions for chronic primary pain, including low level laser therapy. Low level laser therapy (LLLT), was defined as the non-invasive application of a single wavelength of light to the skin over the injured area using a probe. When assessing LLLT versus sham laser therapy for quality of life, very low quality evidence from 6 studies with 276 participants showed a clinically important benefit of laser therapy compared to sham laser therapy at ≤3 months. Low to moderate quality evidence from 2 studies with 110 participants showed both a clinically important benefit of laser therapy (physical subscale) and no clinically important difference (mental subscale) compared to sham laser therapy at ≤3 months. Low quality evidence from 2 studies with 117 participants showed no clinically important difference compared to sham laser therapy at >3 months. For pain reduction, very low quality evidence from 13 studies with 558 participants showed a clinically important benefit of laser therapy compared to sham laser therapy at ≤3 months. Moderate quality evidence from 2 studies with 71 participants showed a clinically important benefit of laser therapy compared to sham laser therapy at >3 months. For Psychological distress, low to moderate quality evidence from 1 study with 44 participants showed no clinically important difference between laser therapy and sham laser therapy at ≤3 months. No evidence was identified for physical function, pain interference, pain selfefficacy, use of healthcare services, and sleep.

DE Oliveira et al. (2022) presented the up-to-date evidence about the effects of low-intensity Light Amplification by Stimulated Emission of Radiation (LASER) and light-emitting diode (LED) (photobiomodulation therapy) on pain control of the most common musculoskeletal conditions. In the rehabilitation setting, patients benefit most when their health providers utilize a multimodal approach combining different types of therapies and when patients take on a significant role in optimal management of their own pain. The use of light as a therapeutic

alternative form of medicine to manage pain and inflammation has been proposed to fill this void. LASER and LED has been shown to reduce inflammation and swelling, promote healing, and reduce pain for an array of musculoskeletal conditions. Authors note that there is evidence that photobiomodulation therapy reduces pain intensity in non-specific knee pain, osteoarthritis, pain post-total hip arthroplasty, fibromyalgia, temporomandibular diseases, neck pain, and low back pain. Upon their review, authors observed that the photobiomodulation therapy offers a non-invasive, safe, drug-free, and side-effect-free method for pain relief of both acute and chronic musculoskeletal conditions as well as fibromyalgia.

#### Other

An evidence-based guideline for the treatment of painful diabetic neuropathy published by American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation (Bril, et al., 2011) notes LLLT is probably not effective for the treatment of this condition and is not recommended.

Wang et al. (2022) critically analyzed the evidence from existing systematic reviews investigating the effectiveness and safety of low-level laser therapy (LLLT) in patients with breast cancer-related lymphedema (BCRL). In addition, an updated and comprehensive systematic review was conducted, which aimed to provide updated evidence about this topic. Seven systematic reviews and ten RCTs met the eligibility criteria. Conflicting results regarding the effectiveness of LLLT were presented by the overview of systematic reviews. The AMSTAR 2 showed that the methodological quality of included systematic reviews was low or critically low quality due to one or more critical weaknesses. The GRADE and GRADE-CERQual showed that the evidence quality was low to very low for most outcomes. The updated systematic review showed that LLLT may offer additional benefits as compared to compression therapies (pneumatic compression or compression bandage), placebo laser, or no treatment for patients with BCRL. However, when compared to other types of active interventions, LLLT did not improve outcomes significantly. None of the treatment-related adverse event was reported. Many trials had a high or unclear risk of bias for two or more items, and our updated systematic review showed low quality of evidence per outcome using GRADE approach. Due to insufficient data and poor quality of evidence, there is uncertain to reach these conclusions that LLLT is superior to another active or negative intervention and is safe. More RCTs of high methodological quality, with large sample sizes and long-term follow-up, are needed to inform clinical guidelines and routine practice. Mahmood et al. (2022) also investigated the efficacy of clinical use of LLLT in the treatment of metastatic breast cancer-related lymphedema. The primary objectives were arm circumference or arm volume, whereas the secondary goals were to assess shoulder mobility and pain severity. Eight clinical trials were analyzed in total. Typically, the included RCTs had good research quality. At four weeks, there was a considerable reduction in arm circumference/volume, and this continued with long-term follow-up. However, no statistically significant change in shoulder mobility or pain severity was seen between the laser and placebo groups at 0-, 1-, 2-, and 3-month short-term follow-up. According to authors and contradictory to the previous review, findings demonstrated that LLLT was successful in diminishing arm circumference and volume than improving shoulder mobility and pain. Based on their analysis, data indicated that laser therapy may be a beneficial treatment option for females with postmastectomy lymphedema. Because of the scarcity of evidence, there is a strong need for well-conducted and longer-duration trials in this field.

## U.S. Food and Drug Administration (FDA)

Since 2002, the U.S. Food and Drug Administration (FDA) granted 510(k) approval to several companies to market lasers that provide LLLT. The LLLT lasers are classified as class II devices under the physical medicine devices section as "Lamp, Non-heating, for Adjunctive Use in Pain Therapy."

Several devices that provide LLLT have been approved under the 501(k) approval process for various indications. These devices include but are not limited to:

- MicroLight 830<sup>TM</sup> (MicroLight Corporation of America, Missouri City, TX)
- Thor Laser System (Thor International Ltd, Amersham, UK)
- Luminex LL Laser System® (Medical Laser Systems, Inc, Branford CT)
- Vectra Genisys Laser System<sup>®</sup> (Chattanooga Group, Hixson, TN)

In the data submitted to the FDA as part of the FDA 510(k) approval process in 2002, the manufacturer of the MicroLight device conducted a double-blind, placebo-controlled study of 135 patients with moderate to severe symptoms of carpal tunnel syndrome who had failed conservative therapy for at least a month.

However, the results of this study have not been published in the peer-reviewed literature, and only a short summary is available in the FDA Summary of Safety and Effectiveness, which does not permit scientific conclusions.

High power therapeutic laser systems granted FDA 510(k) approval as "Infrared lamp", for therapeutic healing and to provide topical heating for the purpose of elevating tissue temperature for temporary relief of minor muscle and joint pain, muscle spasm, pain and stiffness associated with minor arthritis, promoting relaxation of muscle tissue, and to temporarily increase local blood circulation. These devices include but are not limited to:

- Diawave Lasers (formerly Avicenna Laser Technology Inc.) (Riviera Beach, FL):Diowave Laser System, AVI HP-7.5, AVI HPLL-12
- Zimmer MedizinSystems (Irvine, CA): OptonPro

# **Coding Information**

Note: 1) This list of codes may not be all-inclusive.

2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

### Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT®*	Description
Codes	
0552T	Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a
	physician or other qualified health care professional

HCPCS	Description
Codes	
S8948	Application of a modality (requiring constant provider attendance) to one or more areas, low-
	level laser, each 15 minutes

ICD-10-CM	Description
Diagnosis	
Codes	
C00.0-	Malignant neoplasm of external lip
C00.1	
C00.3-	Malignant neoplasm of lip, inner aspect
C00.4	
C00.6	Malignant neoplasm of commissure of lip, unspecified
C00.8	Malignant neoplasm of overlapping sites of lip
C00.9	Malignant neoplasm of lip, unspecified
C01	Malignant neoplasm of base of tongue
C02.0-	Malignant neoplasm of other parts of tongue
C02.8	
C03.0-	Malignant neoplasm of gum
C03.1	
C04.0-	Malignant neoplasm of floor of mouth
C04.9	
C05.0-	Malignant neoplasm of palate
C05.9	
C06.0-	Malignant neoplasm of other and unspecified parts of mouth
C06.9	
C07	Malignant neoplasm of parotid gland
C08.0-	Malignant neoplasm of other and unspecified major salivary glands
C08.9	

C09.0-	Malignant neoplasm of tonsil
C09.9	
C10.0-	Malignant neoplasm of oropharynx
C10.9	
C11.0-	Malignant neoplasm of nasopharynx
C11.9	
C12	Malignant neoplasm of pyriform sinus
C13.0-	Malignant neoplasm of hypopharynx
C13.9	
C14.0-	Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx
C14.8	manginana noopiaann ar aana an aonnoa onoo in aro np, araa aariiy anaa pilaanyiin
C15.3-	Malignant neoplasm of esophagus
C15.9	I wailightent neoplasm of esophiagas
C16.0-	Malignant neoplasm of stomach
C16.9	I wang harit neoplasm of stomach
C17.0-	Malignant neoplasm of small intestine
C17.0-	ivialignant neoplasm of small intestine
C17.9	Malianant nagalage of calan
C18.9	Malignant neoplasm of colon
	Malian ant nearlance of next-sinus sidiometrics
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C21.0-	Malignant neoplasm of anus and anal canal
C21.8	
C22.0-	Malignant neoplasm of liver and intrahepatic bile ducts
C22.9	
C23	Malignant neoplasm of gallbladder
C24.0-	Malignant neoplasm of other parts of biliary tract
C24.8	
C25.0-	Malignant neoplasm of pancreas
C25.9	
C26.0-	Malignant neoplasm of other and ill-defined digestive organs
C26.9	g
C30.0-	Malignant neoplasm of nasal cavity and middle ear
C30.1	I mangram neophaon or riacar oa my ana mhaale oar
C31.0-	Malignant neoplasm of accessory sinuses
C31.9	Manghant hoopidom of dooddory amadod
C32.0-	Malignant neoplasm of larynx
C32.9	Wanghant hoopiashi or laryhx
C33	Malignant neoplasm of trachea
C34.01-	0 1
C34.01- C34.02	Malignant neoplasm of main bronchus
	Malignant pagelogm of upper labor branchus or lives
C34.11-	Malignant neoplasm of upper lobe, bronchus or lung
C34.2	Malian ant magnificant of law and the description of law and the descriptio
C34.31-	Malignant neoplasm of lower lobe, bronchus or lung
C34.32	
C34.81-	Malignant neoplasm of overlapping sites of bronchus and lung
C34.82	
C34.91-	Malignant neoplasm of unspecified part of bronchus or lung
C34.92	
C37	Malignant neoplasm of thymus
C38.0-	Malignant neoplasm of heart, mediastinum and pleura
C38.8	
C39.0-	Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic
C39.9	organs
C40.01-	Malignant neoplasm of scapula and long bones of upper limb
C40.02	

C40.11- C40.12	Malignant neoplasm of short bones of upper limb
C40.21-	Malignant neoplasm of long bones of lower limb
C40.22	M. Para and manufacture of all and have a of Lauren Park
C40.31-	Malignant neoplasm of short bones of lower limb
C40.32	
C40.81-	Malignant neoplasm of overlapping sites of bone and articular cartilage of limb
C40.82	NA Franciska sankara sa faran sa 26 a labara sa sa lababa sa sa fina sa sa fina la
C40.91- C40.92	Malignant neoplasm of unspecified bones and articular cartilage of limb
C41.0-	Malignant neoplasm of bone and articular cartilage of other and unspecified sites
C41.9	Wallyhalit heoplastif of bothe and articular cartilage of other and drispectified sites
C43.0	Malignant melanoma of lip
C43.111-	Malignant melanoma of right eyelid, including canthus
C43.112	
C43.121-	Malignant melanoma of left eyelid, including canthus
C43.122	
C43.21-	Malignant melanoma of ear and external auricular canal
C43.22	, and the second
C43.31-	Malignant melanoma of the nose and other parts of face
C43.39	
C43.4	Malignant melanoma of scalp and neck
C43.51-	Malignant melanoma of trunk
C43.59	
C43.61-	Malignant melanoma of upper limb, including shoulder
C43.62	
C43.71-	Malignant melanoma of lower limb, including hip
C43.72	
C43.8	Malignant melanoma of overlapping sites of skin
U43.0	
C43.6 C43.9	Malignant melanoma of skin, unspecified
C43.9 C44.00-	
C43.9 C44.00- C44.09	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip
C43.9 C44.00- C44.09 C44.1021-	Malignant melanoma of skin, unspecified
C43.9 C44.00- C44.09 C44.1021- C44.1022	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091-	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091- C44.1092	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091- C44.1092 C44.1121-	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091- C44.1092 C44.1121- C44.1122	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091- C44.1092 C44.1121- C44.1122 C44.1191-	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091- C44.1121- C44.1122 C44.1121- C44.1191- C44.1192	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus Basal cell carcinoma of skin of left eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091- C44.1121- C44.1122 C44.1191- C44.1192 C44.1121-	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1091- C44.1092 C44.1121- C44.1122 C44.1191- C44.1192 C44.1221- C44.1222	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus Basal cell carcinoma of skin of left eyelid, including canthus Squamous cell carcinoma of skin of right eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1092 C44.1092 C44.1121- C44.1122 C44.1191- C44.1192 C44.1221- C44.1221- C44.1291-	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus Basal cell carcinoma of skin of left eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091- C44.1092 C44.1121- C44.1122 C44.1191- C44.1192 C44.1221- C44.1222 C44.1291- C44.1292	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus Basal cell carcinoma of skin of left eyelid, including canthus Squamous cell carcinoma of skin of right eyelid, including canthus Squamous cell carcinoma of skin of left eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1092 C44.1121- C44.1122 C44.1191- C44.1192 C44.1221- C44.1222 C44.1291- C44.1292 C44.1321-	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus Basal cell carcinoma of skin of left eyelid, including canthus Squamous cell carcinoma of skin of right eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091- C44.1092 C44.1121- C44.1122 C44.1191- C44.1192 C44.1221- C44.1291- C44.1292 C44.1321- C44.1321- C44.1322	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus Basal cell carcinoma of skin of left eyelid, including canthus Squamous cell carcinoma of skin of right eyelid, including canthus Squamous cell carcinoma of skin of left eyelid, including canthus Sebaceous cell carcinoma of skin of right eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1092 C44.1121- C44.1122 C44.1191- C44.1192 C44.1221- C44.1222 C44.1291- C44.1292 C44.1321-	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus Basal cell carcinoma of skin of left eyelid, including canthus Squamous cell carcinoma of skin of right eyelid, including canthus Squamous cell carcinoma of skin of left eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091- C44.1092 C44.1121- C44.1122 C44.1191- C44.1192 C44.1221- C44.1222 C44.1291- C44.1292 C44.1321- C44.1321- C44.1321- C44.1321-	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus Basal cell carcinoma of skin of left eyelid, including canthus Squamous cell carcinoma of skin of right eyelid, including canthus Squamous cell carcinoma of skin of left eyelid, including canthus Sebaceous cell carcinoma of skin of right eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091- C44.1092 C44.1121- C44.1122 C44.1191- C44.1192 C44.1221- C44.1222 C44.1291- C44.1321- C44.1322 C44.1391- C44.1391- C44.1392	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus Basal cell carcinoma of skin of left eyelid, including canthus Squamous cell carcinoma of skin of right eyelid, including canthus Squamous cell carcinoma of skin of left eyelid, including canthus Sebaceous cell carcinoma of skin of right eyelid, including canthus Sebaceous cell carcinoma of skin of left eyelid, including canthus Other specified malignant neoplasm of skin of right eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091- C44.1092 C44.1121- C44.1122 C44.1191- C44.1192 C44.1221- C44.1222 C44.1291- C44.1321- C44.1322 C44.1391- C44.1392 C44.1391- C44.1392 C44.1391-	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus Basal cell carcinoma of skin of left eyelid, including canthus Squamous cell carcinoma of skin of right eyelid, including canthus Squamous cell carcinoma of skin of left eyelid, including canthus Sebaceous cell carcinoma of skin of right eyelid, including canthus Sebaceous cell carcinoma of skin of left eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1092 C44.1121- C44.1122 C44.1191- C44.1192 C44.1221- C44.1292 C44.1291- C44.1321- C44.1322 C44.1391- C44.1392 C44.1991- C44.1992	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus Basal cell carcinoma of skin of left eyelid, including canthus Squamous cell carcinoma of skin of right eyelid, including canthus Squamous cell carcinoma of skin of left eyelid, including canthus Sebaceous cell carcinoma of skin of right eyelid, including canthus Sebaceous cell carcinoma of skin of left eyelid, including canthus Other specified malignant neoplasm of skin of right eyelid, including canthus Other specified malignant neoplasm of skin of left upper eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091- C44.1092 C44.1121- C44.1122 C44.1191- C44.1192 C44.1221- C44.1291- C44.1292 C44.1321- C44.1322 C44.1391- C44.1392 C44.1991- C44.1992 C44.1991- C44.1992 C44.1992 C44.202-	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus Basal cell carcinoma of skin of left eyelid, including canthus Squamous cell carcinoma of skin of right eyelid, including canthus Squamous cell carcinoma of skin of left eyelid, including canthus Sebaceous cell carcinoma of skin of right eyelid, including canthus Sebaceous cell carcinoma of skin of left eyelid, including canthus Other specified malignant neoplasm of skin of right eyelid, including canthus
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091- C44.1092 C44.1121- C44.1122 C44.1191- C44.1192 C44.1221- C44.1222 C44.1291- C44.1321- C44.1321- C44.1392 C44.1391- C44.1392 C44.1991- C44.1992 C44.1991- C44.202- C44.209	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip  Unspecified malignant neoplasm of skin of right eyelid, including canthus  Unspecified malignant neoplasm of skin of left eyelid, including canthus  Basal cell carcinoma of skin of right eyelid, including canthus  Basal cell carcinoma of skin of left eyelid, including canthus  Squamous cell carcinoma of skin of right eyelid, including canthus  Squamous cell carcinoma of skin of left eyelid, including canthus  Sebaceous cell carcinoma of skin of right eyelid, including canthus  Sebaceous cell carcinoma of skin of left eyelid, including canthus  Other specified malignant neoplasm of skin of right eyelid, including canthus  Unspecified malignant neoplasm of skin of left upper eyelid, including canthus  Unspecified malignant neoplasm of skin of ear and external auricular canal
C43.9 C44.00- C44.09 C44.1021- C44.1022 C44.1091- C44.1092 C44.1121- C44.1122 C44.1191- C44.1192 C44.1221- C44.1291- C44.1292 C44.1321- C44.1322 C44.1391- C44.1392 C44.1991- C44.1992 C44.1991- C44.1992 C44.1992 C44.202-	Malignant melanoma of skin, unspecified Other and unspecified malignant neoplasm of skin of lip Unspecified malignant neoplasm of skin of right eyelid, including canthus Unspecified malignant neoplasm of skin of left eyelid, including canthus Basal cell carcinoma of skin of right eyelid, including canthus Basal cell carcinoma of skin of left eyelid, including canthus Squamous cell carcinoma of skin of right eyelid, including canthus Squamous cell carcinoma of skin of left eyelid, including canthus Sebaceous cell carcinoma of skin of right eyelid, including canthus Sebaceous cell carcinoma of skin of left eyelid, including canthus Other specified malignant neoplasm of skin of right eyelid, including canthus Other specified malignant neoplasm of skin of left upper eyelid, including canthus

C44.222-	Squamous cell carcinoma of skin of ear and external auricular canal
C44.229	
C44.292-	Other specified malignant neoplasm of skin of ear and external auricular canal
C44.299	
C44.301-	Unspecified malignant neoplasm of skin of nose and other parts of face
C44.309	
C44.311-	Basal cell carcinoma of skin of nose and other parts of face
C44.319	
C44.321-	Squamous cell carcinoma of skin of nose and other parts of face
C44.329	
C44.391-	Other specified malignant neoplasm of skin of nose and other parts of face
C44.399	
C44.40-	Other and unspecified malignant neoplasm of skin of scalp and neck
C44.49	Others and the second s
C44.500-	Other and unspecified malignant neoplasm of skin of trunk
C44.509	Developil control of the food
C44.510-	Basal cell carcinoma of skin of trunk
C44.519	Cauchage call parainame of akin of the inte
C44.520-	Squamous cell carcinoma of skin of trunk
C44.529	Other an arified median and a content of this of this life
C44.590-	Other specified malignant neoplasm of skin of trunk
C44.599	Unapposited malignant populary of skip of upper limb, including about as
C44.602-	Unspecified malignant neoplasm of skin of upper limb, including shoulder
C44.609	Decel cell consistence of this of consentingly including the colden
C44.612-	Basal cell carcinoma of skin of upper limb, including shoulder
C44.619	Cauchage call paraisons of ckin of upper limb, including abouter
C44.622- C44.629	Squamous cell carcinoma of skin of upper limb, including shoulder
C44.629	Other specified malignant neoplasm of skin of upper limb, including shoulder
C44.699	Other specified manigrant neoplasm of skin of upper limb, including shoulder
C44.702-	Unspecified malignant neoplasm of skin of lower limb, including hip
C44.709	Choposinos mangriant noopisom of skin or lower limb, molecumy mp
C44.712-	Basal cell carcinoma of skin of lower limb, including hip
C44.719	д
C44.722-	Squamous cell carcinoma of skin of lower limb, including hip
C44.729	
C44.792-	Other specified malignant neoplasm of skin of lower limb, including hip
C44.799	
C44.80-	Other and unspecified malignant neoplasm of overlapping sites of skin
C44.89	
C44.90-	Other and unspecified malignant neoplasm of skin, unspecified
C44.99	
C45.0-	Mesothelioma
C45.9	
C46.0-	Kaposi's sarcoma
C46.4	
C46.51-	Kaposi's sarcoma of lung
C46.52	
C46.7	Kaposi's sarcoma of other sites
C46.9	Kaposi's sarcoma, unspecified
C47.0	Malignant neoplasm of peripheral nerves of head, face and neck
C47.11-	Malignant neoplasm of peripheral nerves of upper limb, including shoulder
C47.12	
C47.21-	Malignant neoplasm of peripheral nerves of lower limb, including hip
C47.22	
C47.3	Malignant neoplasm of peripheral nerves of thorax

0.47.4	
C47.4	Malignant neoplasm of peripheral nerves of abdomen
C47.5	Malignant neoplasm of peripheral nerves of pelvis
C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system
C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified
C48.0-	Malignant neoplasm of retroperitoneum and peritoneum
C48.8	
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck
C49.11-	Malignant neoplasm of connective and soft tissue of upper limb, including shoulder
C49.12	
C49.21-	Malignant neoplasm of connective and soft tissue of lower limb, including hip
C49.22	
C49.3	Malignant neoplasm of connective and soft tissue of thorax
C49.4	Malignant neoplasm of connective and soft tissue of abdomen
C49.5	Malignant neoplasm of connective and soft tissue of pelvis
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue
C49.9	Malignant neoplasm of overlapping sites of connective and soft tissue, unspecified
	· ·
C49.A0-	Gastrointestinal stromal tumor
C49.A9	Market and agreement of the
C4A.0	Merkel cell carcinoma of lip
C4A.111-	Merkel cell carcinoma of right eyelid, including canthus
C4A.112	
C4A.121-	Merkel cell carcinoma of left eyelid, including canthus
C4A.122	
C4A.21-	Merkel cell carcinoma of ear and external auricular canal
C4A.22	
C4A.30-	Merkel cell carcinoma of other and unspecified part of face
C4A.39	
C4A.4	Merkel cell carcinoma of scalp and neck
C4A.51-	Merkel cell carcinoma of trunk
C4A.59	
C4A.61-	Merkel cell carcinoma of upper limb, including shoulder
C4A.62	
C4A.71-	Merkel cell carcinoma of lower limb, including hip
C4A.72	
C4A.8	Merkel cell carcinoma of overlapping sites
C4A.9	Merkel cell carcinoma, unspecified
C50.011-	Malignant neoplasm of nipple and areola, female
C50.012	
C50.021-	Malignant neoplasm of nipple and areola, male
C50.022	
C50.111-	Malignant neoplasm of central portion of breast, female
C50.112	
C50.121-	Malignant neoplasm of central portion of breast, male
C50.122	
C50.211-	Malignant neoplasm of upper-inner quadrant of breast, female
C50.212	
C50.221-	Malignant neoplasm of upper-inner quadrant of breast, male
C50.222	
C50.311-	Malignant neoplasm of lower-inner quadrant of breast, female
C50.312	·
C50.321-	Malignant neoplasm of lower-inner quadrant of breast, male
C50.322	

	,
C50.411-	Malignant neoplasm of upper-outer quadrant of breast, female
C50.412	
C50.421-	Malignant neoplasm of upper-outer quadrant of breast, male
C50.422	M.E. and a continuous floring and a continuous formation and formation and floring flo
C50.511-	Malignant neoplasm of lower-outer quadrant of breast, female
C50.512	Maliana and manufacture and formation and all and a financial models
C50.521-	Malignant neoplasm of lower-outer quadrant of breast, male
C50.522	Malignant neoplasm of axillary tail of breast, female
C50.611- C50.612	Malignant neoplasm of axiliary tall of breast, female
C50.621-	Malignant neoplasm of axillary tail of breast, male
C50.622	Manghant neoplasm of axillary tall of breast, male
C50.811-	Malignant neoplasm of overlapping sites of breast, female
C50.812	Manghant neeplacin or evenapping cites of broadt, female
C50.821-	Malignant neoplasm of overlapping sites of breast, male
C50.822	g
C50.911-	Malignant neoplasm of breast of unspecified site, female
C50.912	
C50.921-	Malignant neoplasm of breast of unspecified site, male
C50.922	
C51.0-	Malignant neoplasm of vulva
C51.9	
C52	Malignant neoplasm of vagina
C53.0-	Malignant neoplasm of cervix uteri
C53.9	
C54.0-	Malignant neoplasm of corpus uteri
C54.9	Maliana and transplanta of the man transplanta of the man and transplanta o
C55	Malignant neoplasm of uterus, part unspecified
C56.1- C56.3	Malignant neoplasm of ovary
C57.01-	Malignant neoplasm of fallopian tube
C57.02	Manghant neoplasm of fallopian tube
C57.11-	Malignant neoplasm of broad ligament
C57.12	manghan noopiasin or stoda ngamon
C57.21-	Malignant neoplasm of round ligament
C57.22	
C57.3	Malignant neoplasm of parametrium
C57.4	Malignant neoplasm of uterine adnexa, unspecified
C57.7	Malignant neoplasm of other specified female genital organs
C57.8	Malignant neoplasm of overlapping sites of female genital organs
C58	Malignant neoplasm of placenta
C60.0-	Malignant neoplasm of penis
C60.9	
C61	Malignant neoplasm of prostate
C62.01-	Malignant neoplasm of undescended testis
C62.02	
C62.11-	Malignant neoplasm of descended testis
C62.12	
C62.91-	Malignant neoplasm of testis, unspecified whether descended or undescended
C62.92	
C63.01-	Malignant neoplasm of epididymis
C63.02	Malianant papelage of an amentic as at
C63.11-	Malignant neoplasm of spermatic cord
C63.12	Malignant negation of ceretum
C63.12 C63.2 C63.7	Malignant neoplasm of scrotum  Malignant neoplasm of other specified male genital organs

C63.8	Malignant neoplasm of overlapping sites of male genital organs
C64.1-	
C64.1-	Malignant neoplasm of kidney, except renal pelvis
C65.1-	Malignant peoplesm of renal polyic
	Malignant neoplasm of renal pelvis
C65.2	
C66.1-	Malignant neoplasm of ureter
C66.2	
C67.0-	Malignant neoplasm of bladder
C67.9	
C68.0-	Malignant neoplasm of other and unspecified urinary organs
C68.9	
C69.01-	Malignant neoplasm of conjunctiva
C69.02	
C69.11-	Malignant neoplasm of cornea
C69.12	
C69.21-	Malignant neoplasm of retina
C69.22	
C69.31-	Malignant neoplasm of choroid
C69.32	
C69.41-	Malignant neoplasm of ciliary body
C69.42	Manghant hoopidom or onlary body
C69.51-	Malignant neoplasm of lacrimal gland and duct
C69.52	I Manghant neoplasm of lacilinal giand and duct
C69.61-	Malignant neoplasm of orbit
	Manighant neoplasm of orbit
C69.62	Malian and a contains of constanting after a force and advance
C69.81-	Malignant neoplasm of overlapping sites of eye and adnexa
C69.82	
C69.91-	Malignant neoplasm of unspecified site of eye
C69.92	
C70.0-	Malignant neoplasm of meninges
C70.9	
C71.0-	Malignant neoplasm of brain
C71.9	
C72.0-	Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system
C72.1	
C72.21-	Malignant neoplasm of olfactory nerve
C72.22	
C72.31-	Malignant neoplasm of optic nerve
C72.32	
C72.41-	Malignant neoplasm of acoustic nerve
C72.42	J
C72.59	Malignant neoplasm of other cranial nerves
C72.9	Malignant neoplasm of central nervous system, unspecified
C72.9	
	Malignant neoplasm of thyroid gland
C74.01-	Malignant neoplasm of cortex of adrenal gland
C74.02	
C74.11-	Malignant neoplasm of medulla of adrenal gland
C74.12	
C74.91-	Malignant neoplasm of unspecified part of adrenal gland
C74.92	
C75.0-	Malignant neoplasm of other endocrine glands and related structures
C75.9	
C76.0-	Malignant neoplasm of other and ill-defined sites
C76.3	
C76.41-	Malignant neoplasm of upper limb
C76.42	J F
- · · · · -	

C76.51-	Malignant neoplasm of lower limb
C76.52	
C76.8	Malignant neoplasm of other specified ill-defined sites
C77.0-	Secondary and unspecified malignant neoplasm of lymph nodes
C77.8	
C78.01-	Secondary malignant neoplasm of lung
C78.02	
C78.1	Secondary malignant neoplasm of mediastinum
C78.2	Secondary malignant neoplasm of pleura
C78.30-	Secondary malignant neoplasm of other and unspecified respiratory organs
C78.39	
C78.4	Secondary malignant neoplasm of small intestine
C78.5	Secondary malignant neoplasm of large intestine and rectum
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
C78.80-	Secondary malignant neoplasm of other and unspecified digestive organs
C78.89	decordary mangriant neoplasm of other and unspecified digestive organs
C79.01-	Secondary malignant neoplasm of kidney and renal pelvis
C79.02	decordary mangriant neoplasm of kidney and tenar pervis
C79.11-	Secondary malignant neoplasm of bladder and other and unspecified urinary organs
C79.19	decordary manghant heopiasm of biadder and other and dispedified diffially organis
C79.2	Secondary malignant neoplasm of skin
C79.31-	Secondary malignant neoplasm of brain and cerebral meninges
C79.31	
C79.40-	Secondary malignant neoplasm of other and unspecified parts of nervous system
C79.49	Secondary mangriant neoplasm of other and unspecified parts of her your system
C79.51-	Secondary malignant neoplasm of bone and bone marrow
C79.52	Geordary mangriant neoplasm or bone and bone marrow
C79.61-	Secondary malignant neoplasm of ovary
C79.63	Occordally manighant modplasm of evaly
C79.71-	Secondary malignant neoplasm of adrenal gland
C79.72	observative manightane mooplasm of autonal glana
C79.81-	Secondary malignant neoplasm of other specified sites
C79.89	Social and manighten the option of outer opposition of outer
C79.9	Secondary malignant neoplasm of unspecified site
C7A.00-	Malignant neuroendocrine tumors
C7A.8	ividiighant neurochdorine tamoro
C7B.00-	Secondary neuroendocrine tumors
C7B.8	Sociality noticenteening territore
C80.0-	Malignant neoplasm without specification of site
C80.2	gg
C81.00-	Hodgkin lymphoma
C81.99	
C82.00-	Follicular lymphoma
C82.99	7 7 <del></del>
C83.00-	Non-follicular lymphoma
C83.99	The second of the second
C84.00-	Mature T/NK-cell lymphomas
C84.99	
C85.10-	Other specified and unspecified types of non-Hodgkin lymphoma
C85.99	
C86.0-	Other specified types of T/NK-cell lymphoma
C86.6	Table Speaking Speaking State South State
C88.0-	Malignant immunoproliferative diseases and certain other B-cell lymphomas
C88.9	James and the state of the stat

C90.00- C90.32	Multiple myeloma and malignant plasma cell neoplasms
C91.00- C91.92	Lymphoid leukemia
C92.00- C92.92	Myeloid leukemia
C93.00- C93.92	Monocytic leukemia
C94.00- C94.82	Other leukemias of specified cell type
C95.00- C95.92	Leukemia of unspecified cell type
C96.0- C96.9	Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue
D00.00- D00.2	Carcinoma in situ of oral cavity, esophagus and stomach
D01.0- D01.9	Carcinoma in situ of other and unspecified digestive organs
D02.0	Carcinoma in situ of larynx
D02.1	Carcinoma in situ of trachea
D02.21- D02.22	Carcinoma in situ of bronchus and lung
D02.3	Carcinoma in situ of other parts of respiratory system
D02.4	Carcinoma in situ of respiratory system, unspecified
D03.0	Melanoma in situ of lip
D03.111- D03.112	Melanoma in situ of right eyelid, including canthus
D03.121- D03.122	Melanoma in situ of left eyelid, including canthus
D03.21- D03.22	Melanoma in situ of ear and external auricular canal
D03.30- D03.39	Melanoma in situ of other and unspecified part of face
D03.4	Melanoma in situ of scalp and neck
D03.51- D03.59	Melanoma in situ of trunk
D03.61- D03.62	Melanoma in situ of upper limb, including shoulder
D03.71- D03.72	Melanoma in situ of lower limb, including hip
D03.8	Melanoma in situ of other sites
D03.9	Melanoma in situ, unspecified
D04.0	Carcinoma in situ of skin of lip
D04.111- D04.112	Carcinoma in situ of skin of right eyelid, including canthus
D04.121- D04.122	Carcinoma in situ of skin of left eyelid, including canthus
D04.21- D04.22	Carcinoma in situ of skin of ear and external auricular canal
D04.30- D04.39	Carcinoma in situ of skin of other and unspecified part of face
D04.4	Carcinoma in situ of skin of scalp and neck
D04.5	Carcinoma in situ of skin of trunk
D04.61- D04.62	Carcinoma in situ of skin of upper limb, including shoulder

D04.71- D04.72 D04.8 Carcinoma in situ of skin of lower limb, including hip D04.9 Carcinoma in situ of skin, unspecified D05.01- D05.01- D05.02 D05.11- D05.12 Intraductal carcinoma in situ of breast D05.82 D05.81- D05.82 D05.91- D05.92 D06.0- D07.0- D07.0- D07.0- D07.0- D07.0- D09.0 Carcinoma in situ of other and unspecified genital organs D09.10- D09.10- D09.11- D09.12- D09.21- D09.21- D09.22 D09.3 Carcinoma in situ of other and unspecified urinary organ D09.8 Carcinoma in situ of thyroid and other endocrine glands D09.9 Carcinoma in situ of other specified sites D09.10- D07.0- D07.0- D07.0- D08.0 Carcinoma in situ of other specified sites D09.10- D09.11- D09.21- D09.21- D09.22 D09.3 Carcinoma in situ of thyroid and other endocrine glands D09.8 Carcinoma in situ of other specified sites D09.9 Carcinoma in situ of other specified D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue K12.31 Oral mucositis (ulcerative), unspecified K12.33 Oral mucositis (ulcerative) due to antineoplastic therapy D10.0 Encounter for antineoplastic radiation therapy Encounter for antineoplastic radiation therapy Encounter for antineoplastic chemotherapy		
D04.8       Carcinoma in situ of skin of other sites         D04.9       Carcinoma in situ of skin, unspecified         D05.01- D05.02- D05.11- D05.12- D05.81- D05.82- D05.89- D05.91- D05.92- D06.0- D07.0- D07.0- D07.0- D07.0- D07.0- D07.0- D07.0- D07.0- D07.0- D09.10- D09.10- D09.10- D09.10- D09.10- D09.10- D09.21- D09.22- D09.22- D09.3       Carcinoma in situ of other and unspecified urinary organ         D09.9       Carcinoma in situ of other specified sites         D09.9       Carcinoma in situ of other specified sites         D09.9       Carcinoma in situ, unspecified         M09.9       Carcinoma in situ of other specified         M09.9       Carcinoma in situ, unspecified         M12.30       Orla mucositis (ulcerative), unspecified         K12.31       Oral mucositis (ulcerative) due to antineoplastic therapy         Z51.0       Encounter for antineoplastic radiation therapy	D04.71-	Carcinoma in situ of skin of lower limb, including hip
D04.9 Carcinoma in situ of skin, unspecified  D05.01- D05.02 D05.11- D05.02 Intraductal carcinoma in situ of breast  D05.11- D05.81- D05.82 Other specified type of carcinoma in situ of breast  D05.91- D06.0- Carcinoma in situ of other and unspecified genital organs  D07.0- D09.0 Carcinoma in situ of other and unspecified urinary organ  D09.10- D09.10- D09.21 Carcinoma in situ of other and unspecified urinary organ  D09.22 Carcinoma in situ of other and unspecified urinary organ  D09.3 Carcinoma in situ of ther and unspecified sites  D09.9 Carcinoma in situ of other specified sites  D09.1 Carcinoma in situ of other specified sites  D09.9 Carcinoma in situ of other specified sites  D09.9 Carcinoma in situ of other specified  E12.30 Oral mucositis (ulcerative), unspecified  E12.31 Oral mucositis (ulcerative) due to antineoplastic therapy  E12.33 Oral mucositis (ulcerative) due to radiation  E12.39 Other oral mucositis (ulcerative)  Encounter for antineoplastic radiation therapy		
D05.01- D05.02 D05.11- D05.12 D05.81- D05.82 D05.91- D06.0- D06.0- D06.0- D07.0- D07.0- D09.0 Carcinoma in situ of bladder D09.10- D09.10- D09.10- D09.21 D09.21 D09.22 Carcinoma in situ of other and unspecified urinary organ D09.21- D09.0 Carcinoma in situ of other and unspecified urinary organ D09.10- D09.10- D09.21 D09.22 Carcinoma in situ of thyroid and other endocrine glands D09.8 Carcinoma in situ of other specified sites D09.9 Carcinoma in situ of other specified D47.29 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue K12.30 Oral mucositis (ulcerative), unspecified K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy K12.33 Oral mucositis (ulcerative) due to radiation K12.39 Other oral mucositis (ulcerative)	D04.8	
D05.02 D05.11- D05.12 D05.81- D05.82 D05.91- D05.92 D06.0- D07.0- D07.0- Carcinoma in situ of other and unspecified urinary organ D09.10- D09.10- D09.11- D09.21- D09.22 D09.3 Carcinoma in situ of thyroid and other endocrine glands D09.8 Carcinoma in situ of other specified sites D09.9 Carcinoma in situ of other specified sites D09.9 Carcinoma in situ of other specified urinary organ D09.10- D09.10- D09.21- D09.22 D09.3 Carcinoma in situ of thyroid and other endocrine glands D09.8 Carcinoma in situ of other specified sites D09.9 Carcinoma in situ, unspecified D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue K12.30 Oral mucositis (ulcerative) due to radiation K12.39 Other oral mucositis (ulcerative) Encounter for antineoplastic radiation therapy	D04.9	Carcinoma in situ of skin, unspecified
D05.11-D05.12		Lobular carcinoma in situ of breast
D05.81- D05.82- D05.91- D05.92- D06.0- D06.9- D07.0- D07.08- D09.0- D09.10- D09.11- D09.21- D09.22- D09.3- D09.8- Carcinoma in situ of thyroid and other endocrine glands D09.8- D09.9- Carcinoma in situ of other specified Scarcinoma in situ of other specified Scarcinoma in situ of thyroid and other endocrine glands D09.9- Carcinoma in situ of other specified Scarcinoma in situ of thyroid and other endocrine glands Scarcinoma in situ of other specified sites Scarc		
D05.81- D05.82  D05.91- D05.92  Unspecified type of carcinoma in situ of breast  D06.9- D06.0- D06.0- D07.0- D07.0- D07.0- D09.0  Carcinoma in situ of other and unspecified genital organs  D09.10- D09.19  D09.21- D09.22  D09.3  Carcinoma in situ of other and unspecified urinary organ  D09.8  Carcinoma in situ of other and unspecified urinary organ  D09.9  Carcinoma in situ of other and unspecified urinary organ  D09.10- D09.10- D09.10- D09.10- D09.11- D09.21- D09.22  D09.3  Carcinoma in situ of thyroid and other endocrine glands  D09.8  Carcinoma in situ of other specified sites  D09.9  Carcinoma in situ of other specified sites  D09.9  Carcinoma in situ of other specified  D47.Z9  Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue  K12.30  Oral mucositis (ulcerative), unspecified  K12.31  Oral mucositis (ulcerative) due to antineoplastic therapy  K12.33  Other oral mucositis (ulcerative)  Encounter for antineoplastic radiation therapy		Intraductal carcinoma in situ of breast
D05.92 D06.0- D06.0- D06.9 D07.0- D07.0- D07.0- D09.0 Carcinoma in situ of other and unspecified genital organs D09.10- D09.12- D09.22 D09.3 Carcinoma in situ of thyroid and other endocrine glands D09.8 Carcinoma in situ of other specified sites D09.9 Carcinoma in situ of thyroid and other endocrine glands D09.10- D09.10- D09.22 D09.3 Carcinoma in situ of thyroid and other endocrine glands D09.8 Carcinoma in situ of other specified sites D09.9 Carcinoma in situ, unspecified D47.729 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue K12.30 Coral mucositis (ulcerative), unspecified K12.31 Coral mucositis (ulcerative) due to antineoplastic therapy K12.33 Other oral mucositis (ulcerative) Encounter for antineoplastic radiation therapy		
D05.91- D05.92  D06.0- D06.9  D07.0- D07.69  D09.0  Carcinoma in situ of other and unspecified genital organs D09.10- D09.19  D09.21  D09.22  D09.3  Carcinoma in situ of thyroid and other endocrine glands D09.8  Carcinoma in situ of other specified sites D09.9  Carcinoma in situ of other specified sites D09.10- D		Other specified type of carcinoma in situ of breast
D05.92 D06.0- D06.9 D07.0- D07.69 Carcinoma in situ of other and unspecified genital organs  D09.0 Carcinoma in situ of bladder  D09.10- D09.19 D09.21- D09.22 D09.3 Carcinoma in situ of thyroid and other endocrine glands  D09.8 Carcinoma in situ of other specified sites  D09.9 Carcinoma in situ of other specified sites  D09.9 Carcinoma in situ of other specified sites  D09.9 Carcinoma in situ of other specified sites  D09.10- D09.10- D09.21- D09.21- D09.21- D09.21- D09.3 Carcinoma in situ of thyroid and other endocrine glands  D09.8 Carcinoma in situ of other specified sites  D09.9 Carcinoma in situ, unspecified  D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue  K12.30 Oral mucositis (ulcerative), unspecified  K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy  K12.33 Oral mucositis (ulcerative) due to radiation  K12.39 Other oral mucositis (ulcerative)  Encounter for antineoplastic radiation therapy		
D06.0- D07.0- D07.0- D07.69  D09.0 Carcinoma in situ of other and unspecified genital organs  D09.10- D09.10- D09.12- D09.22  D09.3 Carcinoma in situ of thyroid and other endocrine glands  D09.8 Carcinoma in situ of other specified sites  D09.9 Carcinoma in situ, unspecified  D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue  K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy  K12.33 Other oral mucositis (ulcerative)  Z51.0 Encounter for antineoplastic radiation therapy		Unspecified type of carcinoma in situ of breast
D07.0- D07.69  D09.0 Carcinoma in situ of other and unspecified genital organs  D09.10- D09.10- D09.19  D09.21- D09.22  D09.3 Carcinoma in situ of thyroid and other endocrine glands  D09.8 Carcinoma in situ of other specified sites  D09.9 Carcinoma in situ, unspecified  D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue  K12.30 Oral mucositis (ulcerative), unspecified  K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy  K12.39 Other oral mucositis (ulcerative)  Z51.0 Encounter for antineoplastic radiation therapy		
D07.0- D07.69  Carcinoma in situ of other and unspecified genital organs  D09.0  Carcinoma in situ of bladder  Carcinoma in situ of other and unspecified urinary organ  D09.19  D09.21- D09.22  D09.3  Carcinoma in situ of thyroid and other endocrine glands  Carcinoma in situ of other specified sites  D09.9  Carcinoma in situ, unspecified  D47.Z9  Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue  K12.30  Oral mucositis (ulcerative), unspecified  K12.31  Oral mucositis (ulcerative) due to antineoplastic therapy  K12.39  Other oral mucositis (ulcerative)  Encounter for antineoplastic radiation therapy		Carcinoma in situ of cervix uteri
D07.69  D09.0 Carcinoma in situ of bladder  D09.10- Carcinoma in situ of other and unspecified urinary organ  D09.21- Carcinoma in situ of eye  D09.22  D09.3 Carcinoma in situ of thyroid and other endocrine glands  D09.8 Carcinoma in situ of other specified sites  D09.9 Carcinoma in situ, unspecified  D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue  K12.30 Oral mucositis (ulcerative), unspecified  K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy  K12.33 Other oral mucositis (ulcerative)  Encounter for antineoplastic radiation therapy		
D09.0 Carcinoma in situ of bladder  D09.10- D09.19 Carcinoma in situ of other and unspecified urinary organ  D09.21- D09.22 Carcinoma in situ of eye  D09.3 Carcinoma in situ of thyroid and other endocrine glands  D09.8 Carcinoma in situ of other specified sites  D09.9 Carcinoma in situ, unspecified  D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue  K12.30 Oral mucositis (ulcerative), unspecified  K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy  K12.33 Oral mucositis (ulcerative) due to radiation  K12.39 Other oral mucositis (ulcerative)  Encounter for antineoplastic radiation therapy		Carcinoma in situ of other and unspecified genital organs
D09.10- D09.21- D09.22 D09.3 Carcinoma in situ of thyroid and other endocrine glands D09.8 Carcinoma in situ of other specified sites D09.9 Carcinoma in situ, unspecified D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue K12.30 Oral mucositis (ulcerative), unspecified K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy K12.33 Other oral mucositis (ulcerative) Encounter for antineoplastic radiation therapy  Encounter for antineoplastic radiation therapy	D07.69	
D09.21- D09.22  D09.3 Carcinoma in situ of thyroid and other endocrine glands D09.8 Carcinoma in situ of other specified sites D09.9 Carcinoma in situ, unspecified D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue K12.30 Oral mucositis (ulcerative), unspecified K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy K12.33 Oral mucositis (ulcerative) due to radiation K12.39 Other oral mucositis (ulcerative) Z51.0 Encounter for antineoplastic radiation therapy		
D09.21 D09.3 Carcinoma in situ of thyroid and other endocrine glands D09.8 Carcinoma in situ of other specified sites D09.9 Carcinoma in situ, unspecified D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue K12.30 Oral mucositis (ulcerative), unspecified K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy K12.33 Oral mucositis (ulcerative) due to radiation K12.39 Other oral mucositis (ulcerative) Encounter for antineoplastic radiation therapy	D09.10-	Carcinoma in situ of other and unspecified urinary organ
D09.3 Carcinoma in situ of thyroid and other endocrine glands  D09.8 Carcinoma in situ of other specified sites  D09.9 Carcinoma in situ, unspecified  D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue  K12.30 Oral mucositis (ulcerative), unspecified  K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy  K12.33 Oral mucositis (ulcerative) due to radiation  K12.39 Other oral mucositis (ulcerative)  Z51.0 Encounter for antineoplastic radiation therapy	D09.19	
D09.3 Carcinoma in situ of thyroid and other endocrine glands D09.8 Carcinoma in situ of other specified sites D09.9 Carcinoma in situ, unspecified D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue K12.30 Oral mucositis (ulcerative), unspecified K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy K12.33 Oral mucositis (ulcerative) due to radiation K12.39 Other oral mucositis (ulcerative) Encounter for antineoplastic radiation therapy		Carcinoma in situ of eye
D09.8 Carcinoma in situ of other specified sites  D09.9 Carcinoma in situ, unspecified  D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue  K12.30 Oral mucositis (ulcerative), unspecified  K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy  K12.33 Oral mucositis (ulcerative) due to radiation  K12.39 Other oral mucositis (ulcerative)  Z51.0 Encounter for antineoplastic radiation therapy	D09.22	
D09.9 Carcinoma in situ, unspecified  D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue  K12.30 Oral mucositis (ulcerative), unspecified  K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy  K12.33 Oral mucositis (ulcerative) due to radiation  K12.39 Other oral mucositis (ulcerative)  Z51.0 Encounter for antineoplastic radiation therapy	D09.3	Carcinoma in situ of thyroid and other endocrine glands
D47.Z9 Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue K12.30 Oral mucositis (ulcerative), unspecified K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy K12.33 Oral mucositis (ulcerative) due to radiation K12.39 Other oral mucositis (ulcerative) Z51.0 Encounter for antineoplastic radiation therapy	D09.8	Carcinoma in situ of other specified sites
K12.30       Oral mucositis (ulcerative), unspecified         K12.31       Oral mucositis (ulcerative) due to antineoplastic therapy         K12.33       Oral mucositis (ulcerative) due to radiation         K12.39       Other oral mucositis (ulcerative)         Z51.0       Encounter for antineoplastic radiation therapy	D09.9	Carcinoma in situ, unspecified
<ul> <li>K12.31 Oral mucositis (ulcerative) due to antineoplastic therapy</li> <li>K12.33 Oral mucositis (ulcerative) due to radiation</li> <li>K12.39 Other oral mucositis (ulcerative)</li> <li>Z51.0 Encounter for antineoplastic radiation therapy</li> </ul>	D47.Z9	Other specified neoplasms of uncertain behavior or lymphoid, hematopoietic and related tissue
K12.33Oral mucositis (ulcerative) due to radiationK12.39Other oral mucositis (ulcerative)Z51.0Encounter for antineoplastic radiation therapy	K12.30	
K12.33Oral mucositis (ulcerative) due to radiationK12.39Other oral mucositis (ulcerative)Z51.0Encounter for antineoplastic radiation therapy	K12.31	Oral mucositis (ulcerative) due to antineoplastic therapy
Z51.0 Encounter for antineoplastic radiation therapy	K12.33	
· · · · · · · · · · · · · · · · · · ·	K12.39	Other oral mucositis (ulcerative)
Z51.11 Encounter for antineoplastic chemotherapy	Z51.0	Encounter for antineoplastic radiation therapy
	Z51.11	Encounter for antineoplastic chemotherapy

## Considered Experimental/Investigational/Unproven:

ICD-10-CM Diagnosis Codes	Description
	All other codes

# Considered Experimental/Investigational/Unproven when used to report high-power Class IV therapeutic laser light therapy:

CPT®* Codes	Description
97039	Unlisted modality (specify type and time if constant attendance)

<sup>\*</sup>Current Procedural Terminology (CPT®) ©2022 American Medical Association: Chicago, IL.

## References

1. Abrisham SM, Kermani-Alghoraishi M, Ghahramani R, Jabbari L, Jomeh H, Zare M. Additive effects of low-level laser therapy with exercise on subacromial syndrome: a 25andomized, double-blind, controlled trial. Clinical Rheumatology 2011;30(10):1341-6.

- 2. Aceituno-Gómez J, Avendaño-Coy J, Gómez-Soriano J, García-Madero VM, Ávila-Martín G, Serrano-Muñoz D, González-González J, Criado-Álvarez JJ. Efficacy of high-intensity laser therapy in subacromial impingement syndrome: a three-month follow-up controlled clinical trial. Clin Rehabil. 2019 Jan 23:269215518824691.
- 3. Ahmad SA, Hasan S, Saeed S, Khan A, Khan M. Low-level laser therapy in temporomandibular joint disorders: a systematic review. J Med Life. 2021;14(2):148-164. Doi:10.25122/jml-2020-0169
- 4. Ahmad MA, A Hamid MS, Yusof A. Effects of low-level and high-intensity laser therapy as adjunctive to rehabilitation exercise on pain, stiffness and function in knee osteoarthritis: a systematic review and meta-analysis. Physiotherapy. 2022;114:85-95. doi:10.1016/j.physio.2021.03.011
- 5. Akkurt E, Kucuksen S, Yılmaz H, Parlak S, Sallı A, Karaca G. Long term effects of high intensity laser therapy in lateral epicondylitis patients. Lasers Med Sci. 2016 Feb;31(2):249-53
- Alayat MSM, Battecha KH, Elsodany AM, et al. Effectiveness of Photobiomodulation Therapy in the Treatment of Myofascial Pain Syndrome of the Upper Trapezius Muscle: A Systematic Review and Meta-Analysis. Photobiomodul Photomed Laser Surg. 2022;40(10):661-674. doi:10.1089/photob.2022.0056
- 7. Alfredo PP, Bjordal JM, Dreyer SH, Meneses SR, Zaguetti G, Ovanessian V, et al. Efficacy of low level laser therapy associated with exercises in knee osteoarthritis: a randomized double-blind study. Clin Rehabil. 2012 Jun;26(6):523-33. Epub 2011 Dec 14.
- 8. Alfredo PP, Bjordal JM, Junior WS, Lopes-Martins RÁB, Stausholm MB, Casarotto RA, Marques AP, Joensen J. Long-term results of a randomized, controlled, double-blind study of low-level laser therapy before exercises in knee osteoarthritis: laser and exercises in knee osteoarthritis. Clin Rehabil. 2018 Feb;32(2):173-178.
- 9. Alfredo PP, Bjordal JM, Junior WS, Marques AP, Casarotto RA. Efficacy of low-level laser therapy combined with exercise for subacromial impingement syndrome: A randomised controlled trial. Clin Rehabil. 2021;35(6):851-860. doi:10.1177/0269215520980984
- American Academy of Orthopaedic Surgeons (AAOS). Management of Carpal Tunnel Syndrome Evidence-Based Clinical Practice Guideline. Published February 29, 2016. Accessed January 19, 2023. Available at URL address: http://www.orthoguidelines.org/guideline-detail?id=1337
- 11. Arora H, Pai KM, Maiya A, Vidyasagar MS, Rajeev A. Efficacy of He-Ne Laser in the prevention and treatment of radiotherapy-induced oral mucositis in oral cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Feb;105(2):180-6.
- 12. Ay S, Doğan SK, Evcik D. Is low-level laser therapy effective in acute or chronic low back pain? Clin Rheumatol. 2010 Apr 23.
- 13. Bal A, Eksioglu E, Gurcay E, Gulec B, Karaahmet O, Cakci A. Low-level laser therapy subacromial impingement syndrome. Photomedicine and Laser Surgery 2009;27(1):31-6.
- 14. Bekhet AH, Ragab B, Abushouk AI, Elgebaly A, Ali OI. Efficacy of low-level laser therapy in carpal tunnel syndrome management: a systematic review and meta-analysis. Lasers Med Sci. 2017 Aug;32(6):1439-1448.
- 15. Biala M. Low-Level Laser Therapy: A Literature Review of the Prevention and Reduction of Oral Mucositis in Patients Undergoing Stem Cell Transplantation. Clin J Oncol Nurs. 2022;26(3):293-299. doi:10.1188/22.CJON.293-299
- 16. Bier JD, Scholten-Peeters WGM, Staal JB, Pool J, van Tulder MW, Beekman E, Knoop J, Meerhoff G, Verhagen AP. Clinical Practice Guideline for Physical Therapy Assessment and Treatment in Patients With Nonspecific Neck Pain. Phys Ther. 2018 Mar 1;98(3):162-171.

- 17. Bingol U, Altan L, Yurtkuran M. Low-power laser treatment for shoulder pain. Photomed Laser Surg. 2005 Oct;23(5):459-64.
- 18. Bjordal JM, Lopes-Martins RA, Joensen J, Couppe C, Ljunggren AE, Stergioulas A, Johnson MI. A systematic review with procedural assessments and meta-analysis of low level laser therapy in lateral elbow tendinopathy (tennis elbow). BMC Musculoskelet Disord. 2008 May 29;9:75.
- 19. Bjordal JM, Lopes-Martins RA, Iversen VV. A randomised, placebo controlled trial of low level laser therapy for activated Achilles tendinitis with microdialysis measurement of peritendinous prostaglandin E2 concentrations. Br J Sports Med. 2006 Jan;40(1):76-80.
- 20. Bjordal JM, Couppe C, Chow RT, Tuner J, Ljunggren EA. A systematic review of low level laser therapy with location-specific doses for pain from chronic joint disorders. Aust J Physiother. 2003;49(2):107-16.
- Bjordal JM, Johnson MI, Lopes-Martins RA, Bogen B, Chow R, Ljunggren AE. Short-term efficacy of physical interventions in osteoarthritic knee pain. A systematic review and meta-analysis of randomised placebo-controlled trials. BMC Musculoskelet Disord. 2007 Jun 22;8:51.
- 22. Bjordal JM, Bensadoun RJ, Tunèr J, Frigo L, Gjerde K, Lopes-Martins RA. A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. Support Care Cancer. 2011 Aug;19(8):1069-77. Epub 2011 Jun 10.
- 23. Blanpied PR, Gross AR, Elliott JM, Devaney LL, Clewley D, Walton DM, Sparks C, Robertson EK. Neck Pain: Revision 2017. J Orthop Sports Phys Ther. 2017 Jul;47(7):A1-A83.
- 24. Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al.; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011 May 17;76(20):1758-65.
- 25. Brosseau L, Robinson V, Wells G, Debie R, Gam A, Harman K, et al. Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD002049.
- 26. Brosseau L, Wells G, Marchand S, Gaboury I, Stokes B, Morin M, et al. Randomized controlled trial on low level laser therapy (LLLT) in the treatment of osteoarthritis (OA) of the hand. Lasers Surg Med. 2005 Mar;36(3):210-9.
- 27. Brosseau L, Welch V, et al. (2000). Low level laser therapy for osteoarthritis and rheumatoid arthritis: a metaanalysis. J Rheumatol 27(8): 1961-9.
- 28. Brosseau L, Welch V, Wells G, deBie R, Gam A, Harman K, et al. (2003). Low level laser therapy (Classes I, II and III) for treating osteoarthritis (Cochrane Review). In The Cochrane Library, Issue 2, Chichester, UK: John Wiley & Sons, Ltd.
- 29. Butts R, Dunning J, Pavkovich R, Mettille J, Mourad F. Conservative management of temporomandibular dysfunction: A literature review with implications for clinical practice guidelines (Narrative review part 2). J Bodyw Mov Ther. 2017 Jul;21(3):541-548.
- 30. Cantero-Téllez R, Villafañe JH, Valdes K, García-Orza S, Bishop MD, Medina-Porqueres I. Effects of High-Intensity Laser Therapy on Pain Sensitivity and Motor Performance in Patients with Thumb Carpometacarpal Joint Osteoarthritis: A Randomized Controlled Trial. Pain Med. 2020 Oct 1;21(10):2357-2365.

- 31. Carcia CR, Martin RL, Houck J, Wukich DK; Orthopaedic Section of the American Physical Therapy Association. Achilles pain, stiffness, and muscle power deficits: achilles tendinitis. J Orthop Sports Phys Ther. 2010 Sep;40(9):A1-26.
- 32. Carvalho PA, Jaguar GC, Pellizzon AC, Prado JD, Lopes RN, Alves FA. Evaluation of low-level laser therapy in the prevention and treatment of radiation-induced mucositis: a double-blind randomized study in head and neck cancer patients. Oral Oncol. 2011 Dec;47(12):1176-81. Epub 2011 Sep 10.
- 33. Cheung WKW, Wu IXY, Sit RWS, Ho RST, Wong CHL, Wong SYS, Chung VCH. Low-level laser therapy for carpal tunnel syndrome: systematic review and network meta-analysis. Physiotherapy. 2020 Mar;106:24-35. doi: 10.1016/j.physio.2019.06.005. Epub 2019 Jun 20.
- 34. Chang WD, Lee CL, Lin HY, Hsu YC, Wang CJ, Lai PT. A Meta-analysis of Clinical Effects of Low-level Laser Therapy on Temporomandibular Joint Pain. J Phys Ther Sci. 2014;26(8):1297-300.
- 35. Choi HW, Lee J, Lee S, Choi J, Lee K, Kim BK, Kim GJ. Effects of high intensity laser therapy on pain and function of patients with chronic back pain. J Phys Ther Sci. 2017 Jun;29(6):1079-1081.
- 36. Chou R, Huffman LH; American Pain Society; American College of Physicians. Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med. 2007 Oct 2;147(7):492-504.
- 37. Chou R, Qaseem A, Snow V, Casey D, Cross JT Jr, Shekelle P, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians; American College of Physicians; American Pain Society Low Back Pain Guidelines Panel. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007 Oct 2;147(7):478-91.
- 38. Chou R, Deyo R, Friedly J, Skelly A, Hashimoto R, Weimer M, et al. Noninvasive Treatments for Low Back Pain. Comparative Effectiveness Review No. 169. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2012-00014-I.) AHRQ Publication No. 16-EHC004-EF. Rockville, MD: Agency for Healthcare Research and Quality; February 2016.
- 39. Chow RT, Johnson MI, Lopes-Martins RA, Bjordal JM. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. Lancet. 2009 Dec 5;374(9705):1897-908.
- 40. Christie A, Jamtvedt G, Dahm KT, Moe RH, Haavardsholm EA, Hagen KB. Effectiveness of nonpharmacological and nonsurgical interventions for patients with rheumatoid arthritis: an overview of systematic reviews. Physical Therapy 2007;87(12):1697-715.
- 41. Clarkson JE, Worthington HV, Furness S, McCabe M, Khalid T, Meyer S. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD001973.
- 42. Clijsen R, Brunner A, Barbero M, Clarys P, Taeymans J. Effects of low-level laser therapy on pain in patients with musculoskeletal disorders. A systemic review and meta-analysis. Eur J Phys Rehabil Med. 2017 Jan 30.
- 43. Cotler HB, Chow RT, Hamblin MR, Carroll J. The Use of Low Level Laser Therapy (LLLT) For Musculoskeletal Pain. MOJ Orthop Rheumatol. 2015;2(5).
- 44. Courville XF, Coe MP, Hecht PJ. Current concepts review: noninsertional Achilles tendinopathy. Foot and Ankle International 2009;30(11):1132-42.

- 45. Dakowicz A, Kuryliszyn-Moskal A, Kosztyła-Hojna B, Moskal D, Latosiewicz R. Comparison of the long¬term effectiveness of physiotherapy programs with low-level laser therapy and pulsed magnetic field in patients with carpal tunnel syndrome. Adv Med Sci. 2011;56(2):270-4.
- 46. DE Oliveira MF, Johnson DS, Demchak T, Tomazoni SS, Leal-Junior EC. Low-intensity LASER and LED (photobiomodulation therapy) for pain control of the most common musculoskeletal conditions. Eur J Phys Rehabil Med. 2022;58(2):282-289. doi:10.23736/S1973-9087.21.07236-1
- 47. de Pedro M, Lopez-Pintor RM, de la Hoz-Aizpurua JL, et al. Efficacy of low-level laser therapy for the therapeutic management of neuropathic orofacial pain: A systematic review. J Oral Facial Pain Headache. 2020;34(1):13–30.
- 48. Dima R, Tieppo Francio V, Towery C, Davani S. Review of Literature on Low-level Laser Therapy Benefits for Nonpharmacological Pain Control in Chronic Pain and Osteoarthritis. Altern Ther Health Med. 2017 Oct 2. pii: AT5647.
- Dingemanse R, Randsdorp M, Koes BW, Huisstede BM. Evidence for the effectiveness of electrophysical modalities for treatment of medial and lateral epicondylitis: a systematic review. Br J Sports Med. 2013; Jan 18.
- 50. Dion S, Wong JJ, Côté P, Yu H, Sutton D, Randhawa K, Southerst D, Varatharajan S, Stern PJ, Nordin M, Chung C, D'Angelo K, Dresser J, Brown C, Menta R, Ammendolia C, Shearer HM, Stupar M, Ameis A, Mior S, Carroll LJ, Jacobs C, Taylor-Vaisey A. Are Passive Physical Modalities Effective for the Management of Common Soft Tissue Injuries of the Elbow?: A Systematic Review by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration. Clin J Pain. 2017 Jan;33(1):71-86.
- 51. Djavid GE, Mehrdad R, Ghasemi M, Hasan-Zadeh H, Sotoodeh-Manesh A, Pouryaghoub G. In chronic low back pain, low level laser therapy combined with exercise is more beneficial than exercise alone in the long term: a randomised trial. Aust J Physiother. 2007;53(3):155-60.
- 52. Dogan SK, Ay S, and Evcik D. The effectiveness of low laser therapy in subacromial impingement syndrome: a randomized placebo controlled double-blind prospective study. Clinics. 2010;65(10): 1019-1022.
- 53. Dong W, Goost H, Lin XB, Burger C, Paul C, Wang ZL, Zhang TY, Jiang ZC, Welle K, Kabir K. Treatments for shoulder impingement syndrome: a PRISMA systematic review and network meta-analysis. Medicine (Baltimore). 2015 Mar;94(10):e510.
- 54. Dostalova T, Hlinakova P, Kasparova M, Rehacek A, Vavrickova L, and Navratil LEffectiveness of physiotherapy and GaAlAs laser in the management of dolytemporomandibular joint disorders. Photomed Laser Surg. 2012;30(5):275-280.
- 55. Doyle AT, Lauber C, Sabine K. The Effects of Low-Level Laser Therapy on Pain Associated With Tendinopathy: A Critically Appraised Topic. J Sport Rehabil. 2016 Feb;25(1):83-90.
- 56. Ekim A, Armagan O, Tascioglu F, Oner C, Colak M. Effect of low level laser therapy in rheumatoid arthritis patients with carpal tunnel syndrome. Swiss Med Wkly. 2007 Jun 16;137(23-24):347-52
- 57. Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy [published correction appears in Cancer. 2021 Oct 1;127(19):3700]. Cancer. 2020;126(19):4423-4431. doi:10.1002/cncr.33100
- 58. Emanet SK, Altan LI, Yurtkuran M. Investigation of the effect of GaAs laser therapy on lateral epicondylitis. Photomed and Laser Surg. 2010;28(3):397-403.

- 59. Emshoff R, Bösch R, Pümpel E, Schöning H, Strobl H. Low-level laser therapy for treatment of temporomandibular joint pain: a double-blind and placebo-controlled trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Apr;105(4):452-6.
- 60. Enwemeka, C. S., J. C. Parker, et al. (2004). The efficacy of low-power lasers in tissue repair and pain control: a meta-analysis study. Photomed Laser Surg 22(4): 323-9.
- 61. Fikácková H, Dostálová T, Navrátil L, Klaschka J. Effectiveness of low-level laser therapy in temporomandibular joint disorders: a placebo-controlled study. Photomed Laser Surg. 2007 Aug;25(4):297-303.
- 62. Franke TP, Koes BW, Geelen SJ, Huisstede BM. Do Patients With Carpal Tunnel Syndrome Benefit From Low-Level Laser Therapy? A Systematic Review of Randomized Controlled Trials. Arch Phys Med Rehabil. 2018 Aug;99(8):1650-1659.
- 63. Glazov G, Yelland M, Emery J. Low-level laser therapy for chronic non-specific low back pain: a meta-analysis of randomised controlled trials. Acupunct Med. 2016 Oct;34(5):328-341.
- 64. Gross AR, Dziengo S, Boers O, Goldsmith CH, Graham N, et al. Low Level Laser Therapy (LLLT) for Neck Pain: A Systematic Review and Meta-Regression. Open Orthop J. 2013 Sep 20;7:396-419.
- 65. Guimarães JS, Arcanjo FL, Leporace G, et al. Effect of low-level laser therapy on pain and disability in patients with plantar fasciitis: A systematic review and meta-analysis. Musculoskelet Sci Pract. 2022;57:102478. doi:10.1016/j.msksp.2021.102478
- 66. Haslerud S, Magnussen LH, Joensen J, Lopes-Martins RA, Bjordal JM. The efficacy of low-level laser therapy for shoulder tendinopathy: a systematic review and meta-analysis of randomized controlled trials. Physiother Res Int. 2015;20(2):108-25.
- 67. He M, Zhang B, Shen N, Wu N, Sun J. A systematic review and meta-analysis of the effect of low-level laser therapy (LLLT) on chemotherapy-induced oral mucositis in pediatric and young patients. Eur J Pediatr. 2018 Jan;177(1):7-17.
- 68. Herpich CM, Amaral AP, Leal-Junior EC, Tosato Jde P, Gomes CA, Arruda ÉE, Glória IP, Garcia MB, Barbosa BR, Rodrigues MS, Silva KL, El Hage Y, Politti F, Gonzalez Tde O, Bussadori SK, Biasotto-Gonzalez DA. Analysis of laser therapy and assessment methods in the rehabilitation of temporomandibular disorder: a systematic review of the literature. J Phys Ther Sci. 2015;27(1):295-301.
- 69. Huang Z, Chen J, Ma J, Shen B, Pei F, Kraus VB. Effectiveness of low-level laser therapy in patients with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2015a Apr 23. pii: S1063-4584(15)01125-5.
- 70. Huang Z, Ma J, Chen J, Shen B, Pei F, Kraus VB. The effectiveness of low-level laser therapy for nonspecific chronic low back pain: a systematic review and meta-analysis. Arthritis Res Ther. 2015b Dec 15;17:360.
- 71. Huang J, Chen J, Xiong S, Huang J, Liu Z. The effect of low-level laser therapy on diabetic foot ulcers: A meta-analysis of randomised controlled trials. Int Wound J. 2021;18(6):763-776. doi:10.1111/iwj.13577
- 72. Hurwitz EL, Carragee EJ, van der Velde G, Carroll LJ, Nordin M, Guzman J, et al.; Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders. Treatment of neck pain: noninvasive interventions: results of the Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders. Spine (Phila Pa 1976). 2008 Feb 15;33(4 Suppl):S123-52.
- 73. Jang H and Lee H. Meta-analysis of pain relief effects by laser irradiation on joint areas. Photomed Laser Surg. 2012;30(8):405-417.

- 74. Jastifer JR, Catena F, Doty JF, Stevens F, Coughlin MJ. Low-Level Laser Therapy for the Treatment of Chronic Plantar Fasciitis: A Prospective Study. Foot Ankle Int. 2014;35(6):566-571.
- 75. Kadhim-Saleh, A., Maganti, H., Ghert, M., Singh, S., & Farrokhyar, F. (2013). Is low-leve laser therapy in relieving neck pain effective? Systematic review and meta-analysis. Rheumatology international, 1-9.
- 76. Kaskutas V, Snodgrass J. Occupational therapy practice guidelines for individuals with work-related injuries and illnesses. Bethesda (MD): American Occupational Therapy Association (AOTA); 2009.
- 77. Kheshie AR, Alayat MS, Ali MM. High-intensity versus low-level laser therapy in th treatment of patients with knee osteoarthritis: a randomized controlled trial. Lasers Med Sci. 2014 Jul;29(4):1371-6.
- 78. Kim GJ, Choi J, Lee S, Jeon C, Lee K. The effects of high intensity laser therapy on pain and function in patients with knee osteoarthritis. J Phys Ther Sci. 2016 Nov;28(11):3197-3199.
- 79. Konstantinovic LM, Cutovic MR, Milovanovic AN, Jovic SJ, Dragin AS, Letic MDj, Miler VM. Low-level laser therapy for acute neck pain with radiculopathy: a double-blind placebo-controlled randomized study. Pain Med. 2010 Aug;11(8):1169-78.
- 80. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy [published correction appears in Cancer. 2015 Apr 15;121(8):1339]. Cancer. 2014;120(10):1453-1461. doi:10.1002/cncr.28592
- 81. Lam LK, Cheing GL. Effects of 904-nm low-level laser therapy in the management of lateral epicondylitis: A randomized controlled trial. Photomed Laser Surg. 2007;25:65-71.
- 82. Lian J, Mohamadi A, Chan JJ, Hanna P, Hemmati D, Lechtig A, Nazarian A. Comparative Efficacy and Safety of Nonsurgical Treatment Options for Enthesopathy of the Extensor Carpi Radialis Brevis: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. Am J Sports Med. 2018 Oct 31:363546518801914.
- 83. Li ZJ, Wang Y, Zhang HF, Ma XL, Tian P, Huang Y. Effectiveness of low-level laser on carpal tunnel syndrome: A meta-analysis of previously reported randomized trials. Medicine (Baltimore). 2016 Aug;95(31):e4424.
- 84. Mahmood D, Ahmad A, Sharif F, Arslan SA. Clinical application of low-level laser therapy (Photo-biomodulation therapy) in the management of breast cancer-related lymphedema: a systematic review. BMC Cancer. 2022;22(1):937. Published 2022 Aug 30. doi:10.1186/s12885-022-10021-8
- 85. Maia ML, Bonjardim LR, Quintans Jde S, Ribeiro MA, Maia LG, Conti PC. Effect of low-level laser therapy on pain levels in patients with temporomandibular disorders: a systematic review. J Appl Oral Sci. 2012 Nov-Dec;20(6):594-602.
- 86. Martimbianco ALC, Ferreira RES, Latorraca COC, Bussadori SK, Pacheco RL, Riera R. Photobiomodulation with low-level laser therapy for treating Achilles tendinopathy: a systematic review and meta-analysis. Clin Rehabil. 2020 Jun;34(6):713-722..
- 87. Mathur RK, Sahu K, Saraf S, Patheja P, Khan F, Gupta PK. Low-level laser therapy as an adjunct to conventional therapy in the treatment of diabetic foot ulcers. Lasers Med Sci. 2017 Feb;32(2):275-282.
- 88. McNeely ML, Arm ijo Olivo S, Magee DJ. A systematic review of the effectiveness of physical therapy interventions for temporomandibular disorders. Phys Ther. 2006 May;86(5):710-25.

- 89. Meireles SM, Jones A, Jennings F, Suda AL, Parizotto NA, Natour J. Assessment of the effectiveness of low-level laser therapy on the hands of patients with rheumatoid arthritis: a randomized double-blind controlled trial. Clinical Rheumatology 2010;29(5):501-9.
- 90. Michener, LA, Walsworth, MK, Burnet EN. Effectiveness of rehabilitation for patients with Subacromial impingement syndrome: a systematic review. Journal of Hand Therapy. 2004;17(2):152-164.
- 91. Naterstad IF, Joensen J, Bjordal JM, Couppé C, Lopes-Martins RAB, Stausholm MB. Efficacy of low-level laser therapy in patients with lower extremity tendinopathy or plantar fasciitis: systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2022;12(9):e059479. Published 2022 Sep 28. doi:10.1136/bmjopen-2021-059479
- 92. National Guideline Centre (UK). Evidence review for electrical physical modalities for chronic primary pain: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. London: National Institute for Health and Care Excellence (NICE); April 2021.
- 93. National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management. NICE guideline [NG59] Published date: November 2016. Accessed January 19, 2023. Available at URL address: https://www.nice.org.uk/guidance/conditions-and-diseases/musculoskeletal-conditions/low-back-pain
- 94. Oken O, Kahraman Y, Ayhan F, Canpolat S, Yorgancioglu ZR, Oken OF. The short-term efficacy of laser, brace, and ultrasound treatment in lateral epicondylitis: a prospective, randomized, controlled trial. J Hand Ther. 2008 Jan-Mar;21(1):63-7.
- 95. Ottawa panel evidence-based clinical practice guidelines for electrotherapy and thermotherapy interventions in the management of rheumatoid arthritis in adults. Phys Ther. 2004;84:1016-1043.
- 96. Patel P, Robinson PD, Baggott C, et al. Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update. Eur J Cancer. 2021;154:92-101. doi:10.1016/j.ejca.2021.05.013
- 97. Pereira Alfredo P et al. Efficacy of low level laser therapy associated with exercises in knee osteoarthritis: a randomized double-blind study. Clin Rehabil. 2011;26(6):523-533.
- 98. Pereira da Silva, J., Alves da Silva, M., Almeida, A., Lombardi, I., Matos, A (2010). Laser Therapy in the Tissue Repair Process: A Literature Review. Photomedicine and Laser Surgery, 28(1), 17-21.
- 99. Peter WF, Jansen MJ, Hurkmans EJ, Bloo H, Dekker J, Dilling RG, et al.; Guideline Steering Committee Hip and Knee Osteoarthritis. Physiotherapy in hip and knee osteoarthritis: development of a practice guideline concerning initial assessment, treatment and evaluation. Acta Reumatol Port. 2011 Jul-Sep;36(3):268-81.
- 100. Peters S, Page MJ, Coppieters MW, Ross M, Johnston V. Rehabilitation following carpal tunnel release. Cochrane Database Syst Rev. 2016 Feb 17;2:CD004158.
- 101. Petrucci A, Sgolastra F, Gatto R, Mattei A, Monaco A. Effectiveness of low-level laser therapy in temporomandibular disorders: a systematic review and meta-analysis. J Orofac Pain. 2011 Fall;25(4):298-307.
- 102. Pieters L, Lewis J, Kuppens K, Jochems J, Bruijstens T, Joossens L, Struyf F. An Update of Systematic Reviews Examining the Effectiveness of Conservative Physical Therapy Interventions for Subacromial Shoulder Pain. J Orthop Sports Phys Ther. 2020 Mar;50(3):131-141. doi: 10.2519/jospt.2020.8498. Epub 2019 Nov 15.

- 103. Rayegani S, Bahrami M, Samadi B, Sedighipour L, Mokhtarirad M, Eliaspoor D. Comparison of the effects of low energy laser and ultrasound in treatment of shoulder myofascial pain syndrome: a randomized single-blinded clinical trial. Eur J Phys Rehabil Med. 2011 Sep;47(3):381-9.
- 104. Reddy, G. K. (2004). Photobiological basis and clinical role of low-intensity lasers in biology and medicine. J Clin Laser Med Surg 22(2): 141-50.
- 105. Redman MG, Harris K, Phillips BS. Low-level laser therapy for oral mucositis in children with cancer. Arch Dis Child. 2022;107(2):128-133. doi:10.1136/archdischild-2020-321216
- 106. Ren H, Liu J, Liu Y, Yu C, Bao G, Kang H. Comparative effectiveness of low-level laser therapy with different wavelengths and transcutaneous electric nerve stimulation in the treatment of pain caused by temporomandibular disorders: A systematic review and network meta-analysis. J Oral Rehabil. 2022;49(2):138-149. doi:10.1111/joor.13230
- 107. Saha S, Smith MEB, Totten A, Fu R, Wasson N, Rahman B, et al.. Pressure Ulcer Treatment Strategies: Comparative Effectiveness. Comparative Effectiveness Review No. 90. (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I.) AHRQ Publication No. 13-EHC003-EF. Rockville, MD: Agency for Healthcare Research and Quality; May 2013. Accessed January 19, 2023. Available at URL address (archived): https://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=1491
- 108. Salmos-Brito JA, de Menezes RF, Teixeira CE, Gonzaga RK, Rodrigues BH, Braz R, Bessa-Nogueira RV, Gerbi ME. Evaluation of low level laser therapy in patients with acute and chronic temporomandibular disorders. Lasers Med Sci. 2013;28(1):57-64.
- 109. Shiri R, Viikari-Juntura E. Low-level laser therapy for neck pain. Lancet. 2010;375(9716):721-2.
- 110. Sims SE, Miller K, Elfar JC, Hammert WC. Non-surgical treatment of lateral epicondylitis: a systematic review of randomized controlled trials. Hand (N Y). 2014;9(4):419-46.
- 111. Skelly AC, Chou R, Dettori JR, Turner JA, Friedly JL, Rundell SD, Fu R, Brodt ED, Wasson N, Winter C, Ferguson AJR. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Jun.
- 112. Skelly AC, Chou R, Dettori JR, Turner JA, Friedly JL, Rundell SD, Fu R, Brodt ED, Wasson N, Kantner S, Ferguson AJR. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Apr. Report No.: 20-EHC009. PMID: 32338846.
- 113. Song HJ, Seo HJ, Lee Y, Kim SK. Effectiveness of high-intensity laser therapy in the treatment of musculoskeletal disorders: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018 Dec;97(51):e13126.
- 114. Song HJ, Seo HJ, Kim D. Effectiveness of high-intensity laser therapy in the management of patients with knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. J Back Musculoskelet Rehabil. 2020;33(6):875-884.
- 115. Stergioulas A, Stergioula M, Aarskog R, Lopes-Martins RA, Bjordal JM. Effects of low-level laser therapy and eccentric exercises in the treatment of recreational athletes with chronic achilles tendinopathy. Am J Sports Med. 2008;36:881-887.
- 116. Taradaj J, et al. Early and long-term results of physical methods in the treatment of venous leg ulcers: randomized controlled trial. Phlebology 2011;26(6):237-45.

- 117. Tascioglu F, Degirmenci NA, Ozkan S, Mehmetoglu O. Low-level laser in the treatment of carpal tunnel syndrome: clinical, electrophysiological, and ultrasonographical evaluation. Rheumatol Int. 2012 Feb;32(2):409-15.
- 118. Tehrani MR, Nazary-Moghadam S, Zeinalzadeh A, Moradi A, Mehrad-Majd H, Sahebalam M. Efficacy of low-level laser therapy on pain, disability, pressure pain threshold, and range of motion in patients with myofascial neck pain syndrome: a systematic review and meta-analysis of randomized controlled trials. Lasers Med Sci. 2022;37(9):3333-3341. doi:10.1007/s10103-022-03626-9
- 119. Toward Optimized Practice. Guideline for the evidence-informed primary care management of low back pain. Edmonton (AB): Toward Optimized Practice; 2011.
- 120. Trudel D, Duley J, Zastrow I, Kerr EW, Davidson R, MacDermid JC. Rehabilitation for patients with lateral epicondylitis: A systematic review. J Hand Ther. 2004;17:243-266.
- 121. Tumilty S, Munn J, Abbott JH, McDonough S, Hurley DA, Baxter GD. Laser therapy in the treatment of achilles tendinopathy: a pilot study. Photomedicine and Laser Surgery 2008;26(1):25-30.
- 122. Valdes K, Marik T. A systematic review of conservative interventions for osteoarthritis of the hand. Journal of Hand Therapy 2010;23(4):334-50.
- 123. Verhagen AP, Schellingerhout JM. Low-level laser therapy for neck pain. Lancet 2010;375(9716):721; author reply 722.
- 124. Vlassov VV, MacLehose HG. Low level laser therapy for treating tuberculosis. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003490.
- 125. Wang Y, Ge Y, Xing W, et al. The effectiveness and safety of low-level laser therapy on breast cancer-related lymphedema: An overview and update of systematic reviews. Lasers Med Sci. 2022;37(3):1389-1413. doi:10.1007/s10103-021-03446-3
- 126. Weber C, Thai V, Neuheuser K, Groover K, Christ O. Efficacy of physical therapy for the treatment of lateral epicondylitis: a meta-analysis. BMC Musculoskelet Disord. 2015 Aug 25;16:223.
- 127. Wong JJ, Shearer HM, Mior S, Jacobs C, Côté P, Randhawa K, et al. Are manual therapies, passive physical modalities, or acupuncture effective for the management of patients with whiplash-associated disorders or neck pain and associated disorders? An update of the Bone and Joint Decade Task Force on Neck Pain and Its Associated Disorders by the OPTIMa collaboration. Spine J. 2016 Dec;16(12):1598-1630.
- 128. Wellington J. Noninvasive and alternative management of chronic low back pain (efficacy and outcomes). Neuromodulation. 2014;17 Suppl 2:24-30.
- 129. World Association of Laser Therapy (WALT). Consensus agreement on the design and conduct of clinical studies with low-level laser therapy and light therapy for musculoskeletal pain and disorders. Photomed Laser Surg. 2006;24:761-762.
- 130. White AR, Rampes H, Liu JP, Stead LF, Campbell J. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD000009.
- 131. Xu GZ, Jia J, Jin L, Li JH, Wang ZY, Cao DY. Low-Level Laser Therapy forTemporomandibular Disorders: A Systematic Review with Meta-Analysis. Pain Res Manag. 2018 May 10;2018:4230583.
- 132. Ye L, Kalichman L, Spittle A, Dobson F, Bennell K. Effects of rehabilitative interventions on pain, function and physical impairments in people with hand osteoarthritis: a systematic review. Arthritis Res Ther. 2011 Feb 18;13(1):R28.

- 133. Youssef EF, Muaidi QI, Shanb AA. Effect of Laser Therapy on Chronic Osteoarthritis of the Knee in Older Subjects. J Lasers Med Sci. 2016 Spring;7(2):112-9.
- 134. Yousefi-Nooraie R, Schonstein E, Heidari K, Rashidian A, Pennick V, Akbari-Kamrani M, et al. Low level laser therapy for nonspecific low-back pain. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005107.
- 135. Yu H, Côté P, Shearer HM, Wong JJ, Sutton DA, Randhawa KA, et al. Effectiveness of passive physical modalities for shoulder pain: systematic review by the Ontario protocol for traffic injury management collaboration. Phys Ther. 2015 Mar;95(3):306-18.
- 136. Yu H, Randhawa K, Côté P, Optima Collaboration. The Effectiveness of Physical Agents for Lower-Limb Soft Tissue Injuries: A Systematic Review. J Orthop Sports Phys Ther. 2016 Jul;46(7):523-54.
- 137. Zhang J, Zhong S, Tan T, Li J, Liu S, Cheng R, Tian L, Zhang L, Wang Y, Liu F, Zhou P, Ye X. Comparative Efficacy and Patient- Specific Moderating Factors of Nonsurgical Treatment Strategies for Frozen Shoulder: An Updated Systematic Review and Network Meta-analysis. Am J Sports Med. 2020 Sep 17:363546520956293.

<sup>&</sup>quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2022 Cigna.